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Abstract	  
Multiple Sclerosis (MS) is an inflammatory autoimmune disease. Several lines of evidence 
indicate that vitamin D sufficiency acts to suppress T-cell driven autoimmune diseases. 
Active vitamin D (1,25(OH)2D3) acts through the vitamin D receptor (VDR), which is a 
nuclear receptor that forms dimers with the retinoic X receptor to bind to vitamin D 
responsive element (VDRE), and alter gene expression. Recently, 110 MS associated loci 
have been identified, where the majority contains VDRE in their gene promoter or regulatory 
region. CD4+ T cells are thought to be the major players in MS, hypothesized from the 
animal model with a MS-like disease, experimental encephalomyelitis (EAE). Active vitamin 
D acts directly on the T lymphocyte VDR to inhibit EAE. Today, there are few genes known 
to be direct targets of VDR in T cells. Naive T cells have low expression of VDR, which can 
be induced upon T cell activation. The upregulation of VDR mediates a shift of active T cells 
to a more anti-inflammatory profile.  
Our lab has studied the vitamin D responsiveness of a selection of MS associated gens. In an 
initial screening, 13 genes were analyzed for vitamin D responsiveness in CD4+ T cells, and 
IL2RA and TAGAP was vitamin D responsive when co-cultured with aCD3/CD28 beads. 
These genes are known to have a role in T cell immunity. s. The aims of this project were to 
study if vitamin D alone is sufficient to trigger gene regulation and to investigate whether 
genotype of MS associated loci correlates with gene expression of TAGAP and IL2RA in 
response to vitamin D. In addition, gene expression of IL2RA and TAGAP in MS patients and 
healthy controls were compared. Samples from MS patients (n = 32) and healthy controls (n 
= 30) were genotyped for rs1738074 and rs7090512 in TAGAP and IL2RA, respectively. 
CD4+ T cells were cultivated and treated with vitamin D as described. Cells were harvested 
after 6, 24 and 48 hours and gene expression was measured by qPCR,  
We concluded that (1) vitamin D (without co-culture with αCD3/CD28) is sufficient for 
regulation of IL2RA and TAGAP expression, they were revealed to be upregulated and 
repressed, respectively, (2) the presence of MS risk variant in IL2RA correlated with higher 
expression in CD4+ T cells treated with vitamin D and co-cultured with αCD3/CD28 beads 
after 24 hours in culture and (3) vitamin D treatment results in lower expression of TAGAP in 
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CD4+ T cells from MS patients than in healthy controls, however, no expression differences 
of IL2RA were observed in these groups.  
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1 Introduction	  
The immune system exists to protect our body from infections and keep us healthy. If the 
immune system of an organism mistakenly recognizes its host as foreign, or becomes 
overactive – autoimmunity occurs. Multiple sclerosis (MS) is one out of many diseases 
that are possibly caused by our own immune system. Although it is unclear what the exact 
disease etiology is, numerous environmental and genetic factors have been shown to be 
associated with the disease. 
This section will briefly address the background of MS and MS genetics, before the 
functions of T lymphocytes and how T cell regulation maintains immune homeostasis are 
described. Bearing in mind the various functions of T cells, vitamin D and its receptor are 
subsequently discussed with respect to their proposed function in T cell regulation before 
the rationale and aims of this study are finally addressed. 
1.1 Multiple	  Sclerosis	  
 Background	  	  1.1.1
MS is a demyelinating and inflammatory disorder affecting the central nervous system 
(CNS). The prevalence of MS cases in Norway is one of the highest prevalence worldwide, 
with approximately 200 cases per 100 000 inhabitants [1]. The cause of MS is unknown, 
however, a general consensus is that MS is a multifactorial disease that develops in 
individuals with a genetic susceptibility, triggered by common environmental factors such 
as smoking, low level of vitamin D in serum and viral infections [2, 3]. In addition, the 
current understanding of the genetic factors involved in MS pathogenesis also implies that 
both epigenetic factors as well as post-genomic regulatory events are involved in disease 
etiology [4]. 
 Vitamin	  D	  and	  MS	  1.1.2
At higher degrees of latitude, and with less exposure of sunlight, an increased risk of MS is 
observed [5, 6]. Low serum levels of 25(OH)D3, the major circulating form of vitamin D, 
are also associated with MS prevalence and disease activity [7, 8]. Recently, a large-scale 
genetic screen also implicated the relevance of vitamin D processing molecules in MS [9]. 
1,25(OH)2D3 signaling modulates both innate and adaptive immune responses [10], even 
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though it was originally described as an essential hormone for mineral bone homeostasis. 
Naive T cells have a low expression of vitamin D receptor (VDR), which is induced upon 
T cell activation [11, 12], whereby 1,25(OH)2D3 mediates a shift towards a more anti-
inflammatory cytokine profile [13]. 
 MS	  genetics	  1.1.3
As early as in the 1970s, the first genetic factors in MS were recognized with the 
identification of DNA variations in the human leukocyte antigen (HLA) (termed MHC 
when not specified to humans) gene complex that conferred MS risk. However, the 
complexity of the genetic component became clearer in recent years when increasingly 
large genome-wide association studies (GWAS) revealed numerous associated risk 
variants outside the HLA-complex [9, 14]. Of the genes found outside the HLA-complex, 
there is a strong overrepresentation of immunologically relevant genes, particularly genes 
known to regulate T cells [9].  
 MS	  susceptibility	  loci	  1.1.4
The HLA gene complex allele DRB1*15:01 has the strongest association with MS in the 
Western populations [9]. The HLA genes are located on the short arm of chromosome 6 at 
p21.3. The gene stretches for almost 4000 kilo bases (kb) of DNA. The HLA molecules 
are encoded on multiple genes that form the complexes. There are now more than 110 
established multiple sclerosis risk variants outside the MHC complex [9] [4] [15]. The 
majority of the non-HLA MS susceptibility loci are located in or close to immune 
regulatory genes. The majority of single nucleotide polymorphisms (SNPs) identified as 
MS risk loci are found in non-coding regions of the genome [9]. When one SNP allele 
occurs more or less frequently in a group of patients than in healthy groups, it is considered 
disease associated and protective associated, respectively. The functional consequence of 
most of these SNPs is not known, however, MS associated SNPs are enriched at 
deoxyribonuclease I (DNase I) hypersensitive sites (DHS). DNase I hypersensitive sites 
are precise and reliable indicators of open and active chromatin, indicating a functional 
role of MS associated SNPs in the regulation of gene transcription [16].  
 MS	  –	  a	  T	  cell	  mediated	  autoimmune	  disease	  1.1.5
CD4+ T cells have for a long time been thought to be the major player in MS pathogenesis, 
hypothesized from animal models with a MS-like disease, experimental autoimmune 
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encephalomyelitis (EAE), induced by myelin reactive T cells [17-20]. Interestingly, 
1,25(OH)2D3 acts directly on the T lymphocyte VDR to inhibit EAE [21]. Both CD4+ T 
cells and CD8+ T cells have been found in MS lesions, where CD4+ T cells predominate 
in acute lesions and CD8+ T cells are more frequently present in chronic lesions [22]. In 
addition, a higher proportion of activated T cells are observed in the peripheral blood of 
MS patients [22], further strengthening the hypothesis that T cell activation is part of the 
disease etiology.  
Autoimmune diseases are caused by the adaptive immune system that initiates an immune 
response directed against healthy cells and tissues, as opposed to tolerance for self-
components. During the development of B- and T-cells, various mechanisms contribute to 
this immunological self-tolerance. Already in thymus and bone marrow, there is a negative 
selection where cells binding too strongly to self-peptides are deleted or arrested. For T-
cells in the thymus, potential auto-reactive cells are terminated when binding too strongly 
to the major histocompatibility complex (MHC) presenting self-peptides. Despite an 
effective negative selection in thymus, some T cells reactive to self-peptides escape 
deletion and enter circulation. For a T-cell mediated autoimmune disease, genes that alter 
the capacity of lymphocytes to become autoreactive may influence development of such 
diseases. Immature B-cells in the bone marrow are exposed to self-antigens expressed by 
different cells circulating in the blood plasma. Immature B-cells with receptors binding 
self-antigens are retained in the bone marrow and given a chance to lose their self-
reactivity by altering their B-cell receptor. In humans, it is thought that autoimmunity is 
induced by a combination of genetic and environmental factors [23].  
1.2 The	  immunology	  of	  T	  lymphocytes	  
The focus of this section is T cell function in the immune response to underline why T 
cells, in particular CD4+ T cells, are interesting to investigate in autoimmune diseases like 
MS. Central to this section will be the activation of T cells, and the different subsets they 
differentiate into. T cells are a type of leukocytes, and comprise the main component of the 
adaptive immune system, together with B cells. Both cell subtypes possess specific antigen 
receptors, which are critical for pathogen recognition and to start an immune response 
upon infection. B cells secrete immunoglobulin (Ig) molecules that target specific antigens, 
whereas T cells are characterized by expression of the T cell receptor (TCR) on the cell 
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surface. The effector function of T cells is carried out through antigen specific interactions 
with other cells in the body.  
 CD4+	  T	  cell	  subsets	  1.2.1
T cells can be grouped depending on the expression of CD4 or CD8 surface molecules, i.e. 
CD4+ or CD8+ T cells. In short, CD4+ T cells – T helper cells - provide help for B cell 
differentiation, and CD8+ T cells are involved in class I restricted lysis of antigen-specific 
targets, and are termed cytotoxic T cells. The CD4 molecule binds to the MHC class II β-
chain, expressed on APCs. In contrast, the CD8 molecule binds the α-domain of the MHC 
class I, which is expressed in most cell types. Here, a focus will be placed on CD4+ T 
cells, as these are the cells used in this study. 
Naive CD4+ T cells can differentiate into several T cell subsets, including T helper 1 
(Th1), T helper 2 (Th2), T helper 17 (Th17) and T regulatory cells (Treg). Each of these 
subsets possesses unique properties for pathogen elimination. Th1 cells produce mainly IL-
2, tumor necrosis factor α (TNF-α) and interferon-γ (IFN-γ), which lead to macrophage 
activation and inflammation. Th2 cells produce IL-4, IL-5, IL-10 and IL-13, mainly 
leading to B cell differentiation and the production of neutralizing antibodies. Th17 cells 
produce mainly IL-17. Tregs, which are CD4+CD25+Foxp3+ T cells, suppress T-cell 
proliferation by producing immunosuppressive cytokines, thereby maintaining 
immunological tolerance [24]. In contrast to other effector T cells, Tregs are not able to 
produce IL-2, but are highly dependent on IL-2 for survival [25].  
 T	  cell	  activation	  and	  co-­‐stimulation	  1.2.2
Upon infection, the challenge for the immune system is to bring naive T cells specific for 
the pathogen into contact with pathogenic antigens, presented by an antigen-presenting cell 
(APC). T cells only recognize peptide antigens when these peptides are presented in a 
complex with MHC on the surface of APCs [26]. 
Dendritic cells (DCs) are examples of APCs, whose main function is to trigger T cell 
responses. Naive T cells first encounter antigens presented by DCs in secondary lymphoid 
tissues, such as lymph nodes. When a T cell encounters an MHC:peptide complex to which 
the TCR binds, the T cell is retained in the lymph node and activated. Though the 
MHC:peptide complex is necessary, this alone is not sufficient to trigger the T cell 
activation and proliferation; a co-stimulatory signal is required. The cell surface protein on 
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naive T cells that receives the co-stimulatory signal is called cluster of differentiation 28 
(CD28) [26]. The CD28 receptor is structurally related to its ligands B7.1 and B7.2 
proteins, also known as CD80 and CD86, presented by APC. In the absence of co-
stimulatory signals, T cells can die or become anergenic, thus arresting proliferation or end 
in apoptosis terminating the initiation of the immune response [27]. 
In addition, expression of co-receptors in T cells is also required for adequate activation. 
These co-receptors are either CD4 or CD8, and assist TCR in APC communication. Via 
their intracellular domains they amplify the signals through the TCR [28]. After T cell 
activation, an additional receptor for B7 becomes expressed on T cells [29], called 
cytotoxic T lymphocyte associated protein 4 (CTLA-4). CTLA-4 is structurally similar to 
CD28, but binds more strongly to B7, and functions as antagonist to CD28 [26]. In other 
words, CTLA-4 reduces the immune response [30], resulting in inhibition of proliferation. 
Hence, the balance between the positive and negative regulatory signals will determine the 
immune response by the T cells.   
 Intracellular	  signaling	  1.2.3
The signal provided upon binding of TCR to the MHC:peptide complex is transmitted to the 
cytoplasmic tails of CD3 proteins, which are associated to the TCR (figure 1.1). The 
cytoplasmic tail of CD3 contains immune-receptor tyrosine-based activation motifs 
(ITAMs), which are associated with cytoplasmic protein tyrosine kinases. CD4 (and CD8) 
have cytoplasmic tails associated with the protein tyrosine kinase Lck. Upon binding of 
MHC ligand, ITAMs are phosphorylated by this kinase, and the cytoplasmic protein tyrosine 
kinase zeta-chain associated protein (ZAP-70) binds the phosphorylated ITAMs, initiating 
intracellular signaling pathways leading to altered gene expression produced by the 
transcription factor nuclear factor of activated T cells (NFAT), nuclear factor kappa-light-
chain-enhancer of activated B cells (NFκB) and activator-protein 1 (AP-1). The combined 
actions of these transcription factors activate genes involved in T cell proliferation and 
differentiation into different T cell subsets, thereby initiating continuation of the immune 
response. 
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Figure 1.1: TCR and MHC:antigen complex in activation of CD4+ T cells in presence of co-
stimulatory molecules. Upon T-cell activation, the MHC complex presents the antigen to a T cell 
through its TCR. In the presence of costimulatory signals, which are delivered by the interaction 
between B7 on the APC with CD28 in T cells, the co-receptor CD4 activates Lck through its 
intracellular ITAM-domain, which in turn phosphorylates ZAP-70, leading to a chain of events 
leading to gene regulation and finally production of cytokines and proliferation and migration of T 
cells. 
 
1.3 Vitamin	  D	  and	  vitamin	  D	  receptor	  
 Transcription	  	  1.3.1
Before vitamin D and its receptor, which is a nuclear receptor and a transcription factor, 
are described in more detail, transcription of genes is briefly discussed. Transcription is the 
process where DNA is copied into a complementary, single stranded RNA strand. This 
process is catalyzed by RNA polymerases and regulated by transcription factors, co-factors 
and chromatin remodeling complexes and histone modifiers. RNA polymerase II 
transcribes genes into mRNA resulting in proteins. Transcription factors are sequence 
specific DNA-bindings proteins that can directly associate with the promoter regions in 
proximity of genes or with enhancers further away, thereby regulating expression of their 
target gene. Depending on the transcription factor as well as their interaction partner and 
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post-translational modifications, the gene can be either enhanced or repressed. Various 
mechanisms are in play to perform these regulations. Transcription factors might block or 
enhance the ability of the RNA polymerase to interact with the coding DNA, and might 
recruit co-activators or co-repressors to the transcription complex [31], or influence 
chromatin state and thus DNA accessibility. 
 Vitamin	  D	  metabolism	  	  1.3.2
Vitamins (from: vital amines) are organic compounds, which organisms are not able to 
synthesize themselves in sufficient amounts [32]. Nowadays, it is known that vitamins 
have an important role in the immune system, and vitamin A and D in particular act on the 
immune system in specific ways [33].  
The major source of vitamin D is sun exposure and diet. Vitamin D exists in a biologically 
inert form and requires hydroxylation by a member of the cytochrome P (CYP) family to 
become the major circulating form of vitamin D, 25-hydroxy vitamin D3 (25(OH)D3), also 
called cholecalciferol. In the liver, several of such CYP 25(OH)D3 enzymes (CYP2R1, 
CYP27A1 and CYP3A4) are found [34]. A second hydroxylation of the circulating form of 
vitamin D, catalyzed by 1α-hydroxylase (encoded by CYP27B1) is required to become its 
active metabolite 1,25-dihydroxy vitamin D3 (1,25(OH)D3), also called calcitriol [34]. The 
vitamin D 24-hydroxylase, encoded by CYP24A1 is able to induce an inactivating pathway 
for vitamin D metabolites. This enzyme is transcriptionally regulated by the levels of 
1,25(OH)2D3, as well as by the fibroblast growth factor 23 (FGF23) [35]. In a negative 
feedback loop, 1,25(OH)2D3 induces expression of CYP24A1, which in turn limits the 
production by repressing the CYP27B1 gene and also initiates degradation of 1,25(OH)2D3  
by catalyzing hydroxylation of 1,25(OH)2 or 25(OH) to produce inactivating metabolites 
[36, 37].  
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Figure 1: Chemical structure of 1,25(OH)2D3. The precursor of the active form of vitamin D 
requires hydroxylation by members of the CYP-family, (CYP2R1, CYP27A1 and CYP3A4) to 
become the major circulating form of vitamin D, 25(OH)D3. A second hydroxylation is required to 
become the active metabolite 1,25(OH)2D3, illustrated in the figure, catalyzed by 1α-hydroxylase 
(CYP27B1).  
 
 VDR	  –	  a	  nuclear	  transcription	  factor	  1.3.3
Signaling through the Vitamin D receptor (VDR) appears to have a dampening immune 
effect as VDR knock out mice (VDR-KO) have a vigorous immune response and 
increased risk of development of autoimmune diseases [38]. Naive T cells have a low 
expression of VDR, which is induced upon activation or exposure to 1,25(OH)2D3 [11, 12]. 
1,25(OH)2D3 has a direct effect on T lymphocyte proliferation and cytokine production 
[39], and it has also been shown to inhibit transcription of the IL-2 gene [40], suggesting 
that up-regulation of VDR serves as a control mechanism to prevent possible overreaction 
of the immune system, and thereby shifting the T cell to a more anti-inflammatory profile. 
Moreover, 1,25(OH)2D3 signaling represses the transcription of genes encoding Th1 pro-
inflammatory cytokines, such as IFN-y, IL17 and IL21 [10, 41].  
Vitamin D receptors (VDRs) are discovered in monocytes and later in APCs, also 
suggesting a role for 1,25(OH)2D3 [11]-[42]-[43]. The Vitamin D receptor belongs to a 
family of ligand induced transcription factors. The protein is 427 amino acids long. The 
two major and functional units are the N-terminal zinc finger DNA binding domain (DBD) 
and the C-terminal ligand-binding domain (LBD)[44], illustrated in figure 1.3. The LBD 
contributes to binding of ligand, dimerization and transcriptional activity.  
Vitamin D, together with its many metabolites are transported in the blood by the vitamin 
D-binding protein (DBP) [45]. The vitamin dissociates from DBP when entering a target 
	   21	  
cell with VDR in the cytoplasm and binds VDR before the complex enters nucleus and 
forms a heterodimer with the nuclear receptor retinoid X receptor (RXR) [45].  
 
Figure 1.3: Schematic drawing of the VDR gene and protein. The different domains of the 427-
amino acid human VDR, located at chromosome 12, are highlighted in the figure. The two major 
functional units are the N-terminal zinc-finger DNA binding domain (DBD) and the C-terminal 
ligand binding (LBD) / heterodimerization domain. (CTE = C-terminal extension) 
 
 VDR	  mediated	  regulation	  of	  gene	  expression	  1.3.4
1,25(OH)2D3 binds VDR with high affinity, and triggers association of the VDR to its 
heterodimeric partner, RXR. The heterodimer then binds to a specific sequence in the 
promoter region of a target gene, called vitamin D responsive elements (VDREs) [46]. 
VDREs consists of a direct repeat of two hexanucleotide half-elements consisting of three 
nucleotides (direct repeat 3, DR3) spacing, or an everted repeat of the two half-elements 
with a six nucleotide (everted repeat 6, ER6) spacing [35], where DR3s are being more 
common [35]. 
Ligand induced heterodimerization of VDR and RXR leads to conformational changes, 
which in turn will recruit co-modulators for transcriptional regulation. It is suggested that 
DNA looping can facilitate contact between co-modulators and enhancer elements to the 
transcriptional start site [46]. Target genes are repressed or activated dependent on whether 
the VDR-RXR heterodimer attracts co-repressor or co-activator proteins. Several genes 
regulated by vitamin D contain only one copy of VDRE in the proximal promoter. 
However, later studies have revealed multiple target genes possessing multiple VDREs 
[47]. These genes, containing multiple VDREs, require all VDR-RXR docking sites for 
maximal induction by 1,25(OH)2D3 [35]. Nontheless, there are VDR regulated genes 
lacking DR3 or ER6, for which the mechanism of regulation is not understood [40].  
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 VDR	  can	  induce	  and	  repress	  gene	  expression	  1.3.5
Numerous gene targets are identified for VDR, and these include genes involved in the 
regulation of calcium metabolism and bone formation. More recently it has also been 
established that VDR may have a role in all phases of T cell differentiation [48]. The 
transcriptional activation of genes regulated by 1,25(OH)2D3 through VDR is currently 
hypothesized to be a multistep process initiated at the promoter region of expressed genes. 
Transactivation requires an open chromatin state at the targets’ gene regulatory region 
[49]. Proteins conferring such activity are recruited by nuclear receptors in response to 
ligand binding. On the other hand, ligand-dependent repression of gene transcription by 
VDR-RXR happens by recruitment of nuclear co-repressors to alter the chromatin in 
proximity to the gene, to heterochromatin. Enzymes that modulate chromatin accessibility 
are those with chromatin remodeling activities and histone modifying abilities, like ATP 
dependent chromatin remodelers and histone methyl- or acetyl- transferases. 
 
Figure 1.2: VDR can act as a transcriptional activator or repressor. The active form of vitamin 
D, 1,25(OH)2D3 mediates its biological effect through binding to the vitamin D receptor (VDR), 
which is a nuclear receptor dimerizing with the retinoic X receptor (RXR). This heterodimer binds 
to vitamin D responsive elements (VDRE) in regulatory regions of genes, and alter gene expression 
according to the co-factor. Recruitment of co-repressors in complex with VDR-RXR leads to 
suppression of gene transcription, whereas recruitment of co-activators enhances gene expression.  
 
1.4 The	  rationale	  of	  this	  study	  
By now, approximately 110 MS susceptibility genes are identified [9, 15] The majority of 
these are thought to play a role in T cell biology. To date, only few genes are proven to be 
direct targets of vitamin D in T cells [42]. Since T cells are important in MS pathogenesis, 
and because low levels of vitamin D in serum are associated with an increased risk of MS, it 
is of interest to see if MS susceptibility genes are regulated by vitamin D in T cells. Using 
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data from previous in silico analyses [47] 80 % of the MS associated gene have one or more 
VDREs in their gene promoter or regulatory regions (-10kb-(+)5kb). Of these genes, 23 
genes contained two or more VDREs. Our lab has studied the vitamin D responsiveness of a 
selection of these genes in T cells. Genes that had either (i) more than one VDRE in their 
regulatory region or (ii) that contained an MS risk SNP and one VDRE in the regulatory 
region of the gene and that were potentially expressed in CD4+ T cells (analyzed in silico;  
[50, 51]) were chosen for the study. 13 genes were analyzed for vitamin D responsiveness in 
CD4+ T cells isolated from six healthy donors. IL2RA was consistently upregulated by 
vitamin D, whereas TAGAP was down regulated in these cells (Berge, unpublished).  
When gene expression was measured in these initial studies, the cells were co-cultured 
with αCD3/28 beads at the time of vitamin D addition and during the whole 1,25(OH)2D3 
treatment period (Berge, unpublished). Whether 1,25(OH)2D3 can modulate expression of  
TAGAP and IL2RA also in the absence of αCD3/28 beads is not known. Both genes did 
contain an MS associated SNP in their promoter and they have at least one VDRE in their 
regulatory gene regions, see table 1.  
Table 1: The genes of interest selected for this study. 
	  	   IL2-­‐Rα	   TAGAP	  
Approved	  name	   Interleukin	  2	  receptor,	  
alpha	  
T-­‐cell	  activation	  Rho	  GTPase	  
activating	  protein	  
Gene	  family	   Interleukin	  and	  interleukin	  
receptors	  
Rho	  GTPase	  activating	  proteins	  
Chromosome	  nr	   10	  	   6	  
Number	  of	  VDREs	   1	   2	  
MS	  associated	  SNPs	   rs2104286	  (Intronic)	  
rs3118470	  (Intronic)	  
rs7090512	  (Promoter)	  
rs212405	  (Promoter)	  
rs1738084	  (5`UTR)	  
 
 Interleukin	  2	  and	  its	  receptor	  1.4.1
One of the genes activated by the intracellular pathway initiated by ZAP-70, encodes the 
cytokine interleukin 2 (IL-2) through the transcription factor NFAT. IL-2 is essential for 
expansion and differentiation of T-cells. In naive T cells, the IL-2 receptor is a heterodimer 
consisting of two chains, a β- and γ-chain, which bind IL-2 with low affinity. However, 
upon T cell activation, the naive T cell expresses a third component, the IL-2 receptor α 
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chain (encoded by the IL2RA gene), also called CD25. The β:γ heterodimer with the α 
chain constitutes a high affinity IL-2 receptor, subsequently making the cell more 
responsive to IL-2. Binding of IL-2 to its high affinity receptor triggers cell proliferation, 
and initiates a series of phosphorylation events. Phosphorylation results in transcriptional 
activation of cytokine targeted genes, including the Treg transcription factor Foxp3 and the 
IL2RA itself [52].The expression of CD25 on effector T cells is reduced through a 
negative feedback loop that will direct the cells towards becoming inactivated [52, 53]. 
CD25 can also be cleaved by enzymes from the T cell surface upon activation, resulting in 
soluble IL2RA (sIL2RA) [54].  
It has been demonstrated in knock-out mice that a deficiency of IL2, IL2RA or IL2RB lead 
to early death due to severe autoimmunity [55, 56], and in humans it is known that that a 
deficiency in the IL2RA gene can result in autoimmunity [57, 58]. In contrast, it is well 
documented that vitamin D results in decreased IL2 secretion in vivo [40, 59, 60], hence 
less ligand for the IL2RA. Evidence supporting an important role of the IL2R-pathway in 
immunological tolerance is revealed by GWAS, which have identified several genetic 
variants in the IL-2/IL2R pathway to be associated with MS [9]. 
 Current	  knowledge	  about	  TAGAP	  1.4.2
TAGAP encodes a protein that is a member of the Rho GTPase-activating (GAP) family 
[61]. T-cell activation RhoGTPase-activating protein (TAGAP) has a role in activation of 
T cells, as suggested by its name. The Rho family of GTPases functions as molecular 
switches that are turned on or off in response to a variety of extracellular stimuli. Rho 
proteins in the guanine-triphosphate protein (GTP)-bound active state can interact with 
effectors leading to diverse biological responses including gene transcription, cell cycle 
regulation and control of apoptosis. TAGAP, being a GAP, induces the inactive form of the 
Rho molecule by dephosphorylation of Rho and thereby releasing GTP, which in turn 
allows guanine-diphospohate protein (GDP) to bind. Guanine nucleotide exchange factors 
(GEFs) on the other hand, stimulate the release of GDP, allowing GTP to bind, returning 
Rho to an active state in a cyclical fashion. TAGAP propagates the inactive form of the 
Rho molecule, illustrated in figure 1.4, which in turn will have a negative effect 
downstream of T cell activation, thereby being an interesting factor to study regarding T-
cell driven autoimmune disease. The expression of TAGAP increases transiently in 
activated T cells and is more highly regulated than other GAP- proteins [61]. 
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Figure 1.4: A simplified biochemical model of the function of T cell activation Rho GTPase- 
activating protein (TAGAP). TAGAP encodes a member of the Rho GTPase activator superfamily1. 
TAGAP increases the rate of Rho GTPases, which hydrolyzes Rho and mediates the inactive form 
of the Rho molecule with negative downstream effects. The figure is inspired from [62]. 
 
High expression levels of TAGAP are shown to be associated with other immune mediated 
diseases like rheumatoid arthritis, coeliac disease and diabetes mellitus [63]. Increased 
TAGAP expression has also been established in severe diseased Chrons` patients [62]. 
1.5 Aims	  of	  the	  study	  
Naive T cells have low expression of VDR, which can be induced upon T cell activation 
[11, 12]. The up-regulation of VDR mediates a shift of active T cells into a more anti-
inflammatory profile [13]. Recent data suggests that vitamin D plays an important role for 
T cell homeostasis in MS as it acts directly on CD4+ T cells to induce cytokine secretion 
and reduce proliferation [12].  
Two of the recently identified MS susceptibility genes (Berge, unpublished); TAGAP and 
IL2RA, known to regulate T cell mediated immunity, contain VDREs in their regulatory 
region, and are thereby possible candidates for vitamin D regulation.  
The main aim of this study is addressed through the following questions: 
1. Is vitamin D alone a sufficient signal to regulate expression of TAGAP and IL2RA 
at both the mRNA- and protein level?  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  http://www.ncbi.nlm.nih.gov/gene/117289	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2. Is there a correlation between the presence of an MS risk variant in both TAGAP 
and IL2RA and their vitamin D response in CD4+ T cells? 
3. Is there a difference in expression of TAGAP and IL2RA in healthy controls and MS 
patients? 
To answer these questions, gene expression was measured in CD4+ T cells by quantitative 
real-time PCR in conditions with and without vitamin D treatment, in the presence and 
absence of T cell activation.  
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2 Methods	  
This section describes the laboratory techniques used in this study. An introduction to each 
method is briefly described prior to the following procedures. Where commercial kits were 
used, the supplied protocols from manufacturer are referred to.  
2.1 Isolation	  of	  human	  CD4+	  T	  cells	  from	  whole	  blood	  
Human primary CD4+ T cells were isolated from whole blood of MS patients and healthy 
volunteers. Authorized personnel collected blood in ethylenediaminetettraacetic acid 
(EDTA) coated tubes to prevent blood from coagulating.  
Human blood needs to be handled with care to avoid possible infections, as blood can be 
potential carrier of infections. Gloves were always used, and gloves and other plastics 
contaminated with blood were disposed in special waste. Cell work requires a sterile 
environment to avoid any kind of contamination, such as bacteria, fungi, virus or other 
cultured cells. To preserve a sterile environment, sterile techniques are at all times 
practiced when working with cells. Procedures are performed in low air flow (LAF) -
benches, and frequently change of gloves in addition to use of sterile equipment and 
filtered tips, all contributes to a sterile environment.  
 Procedure	  for	  isolation	  of	  PBMC	  from	  whole	  blood	  2.1.1
Peripheral blood mononuclear cells (PBMC) can be isolated from whole blood using 
density gradient centrifugation [64] (Lymphoprep). In this method, erythrocytes and 
granulocytes will sediment through the medium while PBMC is held at the sample/medium 
interphase, illustrated in figure 2.1. Following this procedure, isolation of desired 
lymphocytes, such as CD4+ T cells can be performed. 
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Figure 2.1: Schematic illustration of PBMC separation with lymphoprep. Lymphoprep (Stem 
cell Technologies) is a density gradient medium that separates PBMC from blood by a density 
gradient generated through centrifugation. Erythrocytes and granulocytes have a higher density 
than lymphoprep and mononuclear cells, which makes the separation of PBMC possible. 
 
Procedure:	  
1. Cover the LAF-bench with paper towels 
2. Add 1 ml of 100 mM EDTA to a cell culture flask, 75 ml. Pipette the freshly 
collected blood to the cell culture flask. Use 10 ml cold Roswell Park Memorial 
Institute (RPMI) 1640 medium (Life Technologies) to wash out the remaining 
blood in the tubes, and transfer this to the cell culture-flask with EDTA and blood. 
3. Dilute the blood by adding RPMI 1640, to a minimum of 20 ml RPMI1640/5ml of 
blood, and mix the content by pipetting. 
4. Prepare 10 ml of room temperature (RT) lymphoprep per 25 ml solution of blood 
and RPMI1640. 
5. Carefully pipette 25 ml of blood/RPMI1640 to a 50 ml tube, use several tubes if 
necessary. Insert a long needle (40 x 1,25 mm, BD Medical) with 10 ml 
lymphoprep through the blood and to the very bottom of the tube. Gently apply 
pressure to the syringe so that the lymphoprep is placed in the bottom, distinct from 
the blood. 
6. Centrifuge by 800 x g for 30 minutes at RT. Be sure to adjust brake to 0 and 
acceleration to 1! 
7. The mononuclear cells have formed a band on the mediums interphase, see figure 
2.1. This can be ”vacuumed” up by using a Pasteur pipette, or a 10 ml pipette. 
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Make sure to avoid the upper layer when transferring the mononuclear cells. 
Transfer the PBMCs to two 50 ml tubes. 
8. Adjust the volume to 50 ml by adding phosphate buffered saline (PBS) to the tubes, 
to reduce the density of the sample. Centrifuge for 10 min, 650 x g at RT to form a 
pellet.  
9. Remove supernatant (SN) from both tubes. Resuspend cells in one of the tubes in 
10 ml PBS before transferring it into the other tube. If more than one tube were 
used, add 10 ml PBS into the first tube to wash out the PBMCs, total volume is 
now 20 ml. Centrifuge for 10 min at 200 x g at RT to wash away blood plates and 
to form a cell pellet.  
10. Carefully remove the supernatant without disturbing the pellet. Add 10 ml PBS and 
resuspend. Take out 50 µl cell suspension for cell count (section 2.2.4). Centrifuge 
at 200 x g at RT to remove all contaminating blood plates. 
11. Carefully remove supernatant, use a 1000 µl pipette for the last ml without 
disturbing the cell pellet. If the isolated cells are to be further processed by 
Dynabeads, add 500 µl Isolation Buffer (PBS with 0,1% BSA and 2 mM EDTA) 
per 50 x 106 cells. See section 2.2.1 for activation with dynabeads 
 Isolation	  of	  CD4+	  T	  cells	  from	  PBMC	  2.1.2
Human primary CD4+ T cells were isolated from PBMC by Dynabeads UntouchedTM 
Human CD4 T cells Kit (InvitrogenTM by Life Technologies). Dynabeads are magnetic, 
monosized and spherical polymer beads used for cell separation. The Dynabeads 
UntouchedTM Human CD4 T cells Kit isolates CD4+ T cells by negative selection, leaving 
the CD4+ T cells in the cell suspension. The isolation procedure is based upon the 
Dynabeads attribution to deplete B cells, NK cells, monocytes, platelets, dendritic cells, 
CD8+ T cells, granulocytes and erythrocytes. The resulting isolated CD4+ T cells are left 
without antibody and beads, thereby being suitable for further analysis. The isolation 
procedure was done according to the protocol supplied by the manufacturer.  
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2.2 Cultivation,	  activation	  and	  vitamin	  D	  treatment	  of	  primary	  
human	  CD4+	  T	  cells	  
Purified CD4+ T cells were cultivated in X-vivo 15TM medium (BioWhittaker ®, Lonza) 
already containing the antibiotic gentamycin and phenol red as pH indicator. X-vivo media 
is optimized for proliferation of purified CD3+ T cells isolated from peripheral blood and 
human tumors2. The cell density was kept at 0.8 x 106 – 1.5 x 106 cells per milliliter (ml) 
X-vivo. To maintain the desired density, 1,0 µl 10 ng/µl of the T-cell growth factor 
interleukin 2 (IL-2; R&D systems) was added per ml of X-vivo. Cultivated cells were 
carefully monitored by cell counting, see section 2.2.4, as well as by microscopy. Cells 
were incubated in 37°C 5% CO2.   
 Activation	  of	  CD4+	  T	  cells	  2.2.1
In order for the isolated CD4+ T cells to proliferate and get activated, the cells need to be 
stimulated. Dynabeads Human T- Activator αCD3/CD28TM (Life Technologies) was used. 
The human T- activator beads are coated with anti-CD3 and anti-CD28 monoclonal 
antibodies, which interact with their corresponding molecules on the T cell surface, 
resulting in an intracellular signaling cascade that leads to activation of the T cells. The 
procedure for T cell activation was performed according to the manufacturers’ instructions, 
where table 1 below shows the requirements.  
Table 1. Reagents for cultivation of human peripheral CD4+ T cells  
Reagent	   Volume	  added	  
Volume	  of	  Dynabeads	   25	  ml	  
Volume	  of	  cell	  suspension	   1	  ml	  
Volume	  of	  IL-­‐2	  (	  10ng/µl)	   1	  ml	  
 
 Vitamin	  D	  treatment	  of	  CD4+	  T	  cells	  	  2.2.2
Human CD4+T cells in culture were treated with the active form of vitamin D, 1,25-
dihydroxy D3 (calcitriol, Sigma Aldrich). Prior to the procedure, the 1,25-dihydroxy D3 was 
solubilized in ethanol (EtOH) to 1 nM, and further diluted 1:100 in preheated X-VIVO, 
where 1 µl was added per ml cell suspension in a total volume of 1x106 cells.  As negative 
control, the vehicle, EtOH, was also diluted 1:100 in preheated X-VIVO and added to the 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2	  http://bio.lonza.com/uploads/tx_mwaxmarketingmaterial/Lonza_BenchGuides_X-­‐VIVO_Media_Information_Sheet.pdf	  
	   31	  
same number of cells in a separate well. As vitamin D is extremely toxic in high 
concentrations, dilutions were done in a fume hood to prevent inhalation. 
Prior to addition of vitamin D/EtOH, the αCD3/CD28 activator Dynabeads were removed 
from the cells. The removal of αCD3/CD28 activator Dynabeads were done by transferring 
the cell suspension to a 15 ml tube, and then put the tube on magnet (Dyna Mag™ -2, 
Invitrogen), allowing the cells to rest for 24 hours in the CO2 incubator. Vitamin D and 
EtOH, with and without αCD3/CD28 activator Dynabeads	  were then added to cell cultures. 
The time point when vitamin D or vehicle was added was designated time 0. Cells were 
harvested as described in the next subsection. 
 Collection	  of	  cell	  lysates	  2.2.3
Cells were collected both for RNA isolation and for generating whole cell lysates. 
Harvesting of the CD4+ T cells was done after treatment as described in the previous 
section, and the specific time points are given in the result section.  
It is critical to stabilize RNA immediately after cell harvesting to ensure high integrity and 
quality of the RNA, both important criteria for subsequent gene expression analysis. RNA 
protect Cell Reagent (Qiagen) was used for stabilization of RNA in cultured cells.   
Procedure	  for	  harvesting	  cells	  on	  RNA	  protect:	  
1. Spin down cells for 5 min, 300 x g at RT. 
2. Discard SN, and resuspend cells in 1 ml PBS. 
3. Spin down as in step 1. 
4. Discard SN. 
5. Roughly mix cell pellet in 350 µl RNA protect. 
6. Store at -70 oC. 
Cell harvesting for protein lysate: The αCD3/CD28 activator Dynabeads were removed 
prior to cell collection to prevent unwanted bands on Western blot, which happen when the 
antibodies are dissolved from the Dynabeads upon heating of the samples with loading 
buffer prior to gel electrophoresis (see section 2.6.3) 
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Procedure	  for	  harvesting	  cells	  to	  generate	  protein	  lysate:	  
1. Spin down cells for 5 min, 300 g at RT. 
2. Discard SN, and resuspend cells in 1 ml PBS. 
3. Spin down as in step 1. 
4. Remove ALL SN. 
5. Store cell pellet in -20°C prior to generating protein lysis, described in section 
2.6.1. 
 Cell	  count	  2.2.4
Quantification of human CD4+ T cells was done by the use of TC20TM automated cell 
counter (Bio-Rad). The cell counter can measure the viability when tryphan blue solution 
(Sigma Aldrich) is mixed in 1:1 ratio to the cell suspension. In addition, the settings on the 
cell counter can be adjusted in order to gate according to size, enabling definition of the 
population of interest. 
Procedure	  for	  cell	  count:	  
1. Mix 10 µl cell suspension with 10 µl tryphan blue. 
2. Pipet 10 µl into Counting Slides dual chamber (Bio-Rad). 
3. Insert the slide into the TC20 automatic cell counter and wait for the cells to be 
counted. 
2.3 Sample	  storage	  –	  MS	  Biobank	  
The MS research group has been collecting material from MS patients and healthy controls 
over the last years. CD4+ T cells have been isolated from from MS patients and healthy 
controls by members of the MS group. Live CD4+ T cells are stored in liquid nitrogen 
(LN), which in this thesis will be referred to as the MS biobank. Samples collected were 
from untreated, female Norwegian MS patients with relapsing-remitting MS (RRMS) aged 
between 18 and 65. These were recruited from the MS clinic at the Department of 
Neurology, Oslo University Hospital. Controls are aged-matched to MS cases, and all 
female.  
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In this study, CD4+ T cells from healthy donors (n = 10) and MS patients (n = 8) from the 
MS biobank were thawed and expanded with αCD3/CD28 coated beads for 7-8 days, as 
described in section 2.3.1, before removal of beads for 24 hours to rest the cells prior to 
addition of vitamin D or vehicle control with or without αCD3/CD28 beads. Prior to 
addition of vitamin D or vehicle with or without αCD3/CD28 beads, an appropriate 
number of cells were frozen down again, described in section 2.3.2. Below is a flow chart 
indicating the major steps during expansion and cultivation of CD4+ T cells, which are 
described in detail in the next subsection.  
 
Figure 2.2: Flow chart showing CD4+ T cell expansion after thawing. Cell density was kept at 
1-1,5 x 106 cells per ml. For each ml of X-vivo added, 1-1,4 µ1 IL-2 was also added. 
 
All cultures were closely monitored by frequent cell count and by microscopy to observe 
morphology/cell size. On average, the cells needed 7-9 days in culture to achieve a 
sufficient number of cells to complete the experiments. To obtain optimal growth- and 
expanding conditions, cell density was kept at 1-1,5 x 106 cells per ml.  
 Thawing	  protocol	  of	  cryopreserved	  cells	  2.3.1
When samples from the biobank are taken into use, it needs to be thawed and cultivated for 
a number of days in order to achieve a sufficient number of cells. The following procedure 
has been developed and optimized for proliferation of CD4+ T cells stored on liquid 
nitrogen. However, some minor modifications must still be taken into account when 
performing this procedure, as cell cultures from different donors do not have the same 
viability or growth rate. 
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Procedure:	  
Day	  1:	  
• Thaw the cells (1 ml) in 37°C water bath, rocking gently until the ice is melted. 
Wipe the outside of the tube with alcohol. 
• Transfer cells to a fresh 15 ml tube with 2 ml room tempered (RT) RPMI1640 
medium. Add 7 ml of RT RPMI (wash cryotube with some of it). 
• Spin cells down immediately (8 min. 1200 rpm at RT) and remove media as soon 
as possible. Use a 1000 µl pipette to remove the last drops of the RPMI. 
• Resuspend cell pellet gently (5 ml pipette) in 1 ml warm (37 oC) X-VIVO medium 
and transfer to a 12 well plate. Wash out the remaining cells (1000 µl pipette) in 1 
ml (37 oC) X-VIVO and add to the 12 well plate.  
• Add 1µl IL-2 (10 ng/µl) per ml X-VIVO, and spread evenly in the well. 
• Wash and add αCD3/28 Dynabeads, see section 2.2.1. 25 µl beads per well.	  
Day	  3:	  
• Transfer the cells from the 12-well plate to a 6-well plate.  
• Add 4 ml pre-heated (37 oC) X-VIVO (with 1,4 µl IL-2/ml medium). 
Day	  4:	  
• Split cells into 2 wells by transferring half the volume (~3 ml) into a new well, and 
add 3 ml pre-heated X-VIVO (with 1,4 µl IL-2/ml medium) to both wells.  
• Leave for 4 nights before harvesting. 
Day	  7:	  
• If the media is turning yellow, add 1 ml new X-VIVO medium. 
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Day	  8:	  
• At this point, the cell amount has increased to >40x106 cells. Dynabeads were 
removed allowing the cells to rest for 24 hours prior to stimulation with vitamin D 
or vehicle control, +/- αCD3/CD28 beads.  
 Cryopreservation	  of	  CD4+	  T	  cells	  2.3.2
CD4+ T cells can be stored for longer periods in liquid nitrogen in the presence of the 
detergent sulfoxide (DMSO), and can be thawed up for cultivation. To achieve the optimal 
conditions for thawing, cells must be frozen by addition of a mixture of fetal calf serum 
(FCS) and DMSO. The DMSO will protect the cells from puncture upon freezing by 
preserving the membrane integrity. For each tube of cells to be thawed up for cultivation in 
the study, described in the previous section, an appropriate number of cells were again 
frozen down after expansion. 
	  Procedure:	  	  
1. Make freezing solution (make 0,5 ml solution per tube of CD4+ T cells to be 
frozen, 2 x 106 CD4+ T cells/tube) If several tubes of the same cell type should be 
frozen, make a “master mix” of 1 ml freezing solution per 4 million cells 
containing 20 % DMSO and 80 % FCS. 
2. Prepare by adding DMSO to serum on ice. Keep on ice until use. 
3. Place cryotubes on ice. 
4. Add slowly (approximately 1 minute), one drop at the time, freezing solution (0,5 
ml per tube to be frozen) to the cells. Keep on ice at all times. Swirl the tube with 
the cells during the procedure.  
5. Mix the whole solution before transferring 1 ml of the solution to chilled cryotubes 
on ice and transfer them to an isopropanol box (4 ºC).  
6. Place the box in -80ºC for minimum 24 hours before transferring them (use the box 
to carry the tubes) to liquid nitrogen. 
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2.4 RNA	  techniques	  
RNA was isolated from cells resuspended in RNA protect, see section 2.2.3. When 
working with RNA, gloves are used at all times and changed frequently as RNases will 
contaminate the samples. RNase catalyzes degradation of RNA. Pipettes, bench, and boxes 
were frequently washed with RNase Away (Qiagen). Filter tips and RNase-free reagents 
were used. RNA-isolations were done in a hood as β-mercaptoethanol (Sigma) is a serious 
irritant and is added to the lysis buffer provided by the RNA isolation kit. 
 RNA	  isolation	  2.4.1
RNA is isolated with the RNeasy Plus Mini Kit using QIAshredder columns for lysate 
homogenization (both from Qiagen). RNA isolation is performed as described in the 
protocol provided by the manufacturer. Briefly, after cell lysis and homogenization, 
genomic DNA is removed by binding to the gDNA eliminator columns, provided by the 
RNeasy Plus Mini Kit. Ethanol is added to the solution enabling proper binding conditions 
for RNA to bind to the RNeasy membrane. RNA is then transferred to RNeasy mini spin 
column (Qiagen), where contaminations are washed away, while the RNA will be bound to 
the membrane in the spin column. The RNA is then eluted in RNase-free H2O. 
After each RNA isolation, 1,5 µl is saved for concentration measurements, described in the 
next subsection. In addition, from each round of RNA isolation (4-8 samples was isolated 
per round), 1,5 µl RNA is taken out from random samples to analyze the RNA integrity on 
the Bioanalyzer, see section 2.4.3 
 Assessment	  of	  nucleic	  acid	  concentration	  2.4.2
Nanodrop 2000 is a micro-volume UV-Vis spectrophotometer for nucleic acid and protein 
quantification. Absorbance is measured at 230 nm, 260 nm and 280 nm. The NanoDrop 
ND-2000 software evaluates the purity of the samples by calculations of the absorbance 
ratios at 230/260 nm and 260/280 nm. The expected ratios of 260/230 nm and 260/280 nm 
are 2,0-2,2 and 1,8-2,0, respectively. Measurements of RNA were done according to the 
manufacturer’s instructions. 
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 RNA	  integrity	  2.4.3
RNA quality is a concern when measuring gene expression. A number of RNA isolations 
have been performed in this project, and a selection of those were picked out for RNA 
integrity measurements.  
The Agilent RNA 6000 Nano Kit (Agilent Technologies) is used to estimate the integrity 
of isolated RNA samples. The samples are loaded onto a chip that contain a special gel 
matrix with an RNA-intercalating dye in a miniature capillary system. The quality of RNA 
is a calculation of the RNA integrity number (RIN) generated by the software 2100 
Bioanalyzer Expert, which also measures the ratio of 28S:18S ribosomal RNA.  
RIN values are numerical assessments of the RNA integrity. RIN is given between 1 and 
10, where 10 represent intact RNA and 1 represent total RNA degradation. A RIN value 
between 6 and 10 is considered sufficient RNA quality to be used for expression profiling. 
The procedure was followed in accordance to the manufacturer’s instructions. 
 Complementary	  DNA	  synthesis	  2.4.4
The enzyme reverse transcriptase (RT) generates complementary DNA (cDNA) from RNA 
template. The cDNA synthesis is done routinely prior to quantitative real time PCR 
(qPCR). Maxima First Strand cDNA Synthesis Kit for RT-qPCR (Thermo Scientific) was 
utilized in accordance to the protocol applied by the kit. The cDNA was stored at -20°C for 
short time storage, or at -80°C for long time storage. 
Reverse transcriptase minus (RT-) negative control is important in the real-time PCR 
reactions to assess for genomic DNA (gDNA) contaminations of the RNA samples. The 
RT- has all components in the reaction mixture, except for the enzyme. In addition, a non-
template control (NTC) is also included to assess for reagent contaminations. NTC 
contains all components except RNA template.  
2.5 Real-­‐time	  PCR	  
 Quantitative	  real-­‐time	  PCR	  2.5.1
qPCR is a technique for amplification and quantification of targeted DNA, or cDNA in the 
case of gene expression. Expression of specific genes can be analyzed by qPCR where the 
amount of DNA is measured after each cycle via fluorescent dyes that gives increasing 
signal in direct proportion to the number of PCR products generated. If a particular 
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sequence is abundant in the sample, amplification is observed in early cycles. If a 
particular sequence is at low concentrations, amplification can be observed at later cycles.  
Before initiation of PCR, the Taqman® probe is intact, and the reporter and quencher have 
a natural affinity for each other, see figure 2.3, thereby allowing fluorescent resonance 
energy transfer (FRET) to occur. During PCR, the primers and probe anneal to the target. 
DNA polymerase extends the primer upstream of the probe. If the probe is attached to the 
correct target sequence, the polymerase 5´nuclease activity cleaves the probe, releasing a 
fragment containing the reporter dye. Once cleavage takes place, the reporter and quencher 
are no longer attached to each other, and the released reporter molecule will not be 
quenched.  
 
Figure 2.3: Schematic illustration of the TaqMan®  assay. Before initiation of PCR, the 
Taqman® probe is intact, and the reporter and quencher have affinity for each other. 
 
In this study, the relative standard curve method was utilized to analyze gene expression. A 
stock of eight-point standard curve with 1:2 dilution-series was made. VIC-labeled TBP 
and 18S rRNA (Life Technlogies) detection probes and gene specific FAM-labeled 
detection probe for IL2RA (taqman assay ID: HS00907777_m1), TAGAP (taqman assay 
ID:HS00299284_m1), VDR (taqman assay ID: HS00172113_m1) and CYP24A1 (taqman 
assay ID: HS00167999_m1) was used in the qPCR runs in this study. Before the main 
qPCR runs, quality controls of the various assays were performed, as well as optimization 
of standard curves. These include (1) check of their specificity by running the PCR product 
on agarose gel (see section 2.5.3), (2) make sure the cDNA synthesis is not saturated by 
making standard curves of RNA, (3) ensure that the standard curves with cDNA are 
approximately 100% efficient reactions, which means a 10-fold increase in PCR amplicon 
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every 3,32 cycle, resulting in a standard curve slope of -3,3, and (4) dilution of samples to 
ensure they are amplified within the standard curve range.  
All qPCR experiment preparations were done according to the instructions delivered by 
Applied Biosystems, Life Technologies, and run on Applied Biosystems ViiaTM 7 Real-
Time PCR system (Life Technologies) and the data was analyzed by Viia™ 7 Software 
(Life Technologies).  
 Single	  nucleotide	  polymorphism	  (SNP)	  genotyping	  2.5.2
Genetic variation analysis is another application of real-time PCR. The technique also uses 
the 5´-nuclease activity of the polymerase. Each predesigned SNP Genotyping Assay 
contains one VIC–labeled probe and one FAM-labeled probe enabling to distinguish 
between the two alleles. The Taqman predesigned SNP assays IDs used were rs7090512 
(taqman assay ID: C_1841420_20) and rs1738074 (taqman assay ID: C_2966098-10). 
DNA from 63 donors (MS patients n = 33, HC n = 30), had previously been extracted by 
members in the MS research group in connection with other research projects. The DNA 
extraction was performed by using a Qiagen Gentra Autopure LS Automated DNA Purifier 
machine, or manually by QIAamp DNA Blood Mini Kit extraction (Qiagen). 12 ng DNA 
from each donor was used for each genotyping assay, and the procedure was done 
according to the manufacturer’s instructions and run on ViiaTM 7 Real-Time PCR system. 
The data was analyzed by Viia™ 7 Software (Life Technologies)  
 Agarose	  gel	  electrophoresis	  2.5.3
Agarose gel electrophoresis is a standard method used to separate DNA molecules 
according to size. As DNA is negatively charged, DNA molecules migrate through the gel 
towards the anode, which is the positively charged electrode.  DNA is visualized under UV 
light in a gel-dock station (GeneGenius Gel Light Imaging System, Syngene). The 
visualization is possible as the DNA is run in an agarose gel containing ethidium bromide 
(EtBR) (MP biomedical). EtBR intercalates into the structure of DNA making it visible in 
UV light. The percentage of agarose influences the migration and separation of the DNA 
molecules. A higher agarose percentage leads to slower migration rate. The percentage 
used in this thesis was 2%. 
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Procedure:	  
1. Mix agarose powder and 1 x Tris-acetate-EDTA (TAE) buffer in accordance to 
your desired percentage of agarose. For 2 % gel, mix as indicated in the table. 
Reagent	   Amount	  
Agarose	   1	  g	  
1xTAE	  buffer	   50	  ml	  
Total	  volume	   50	  ml	  
 
2. Boil solution until the agarose powder is completely dissolved. 
3. Cool the solution to approximately 50ºC and add 2 µl (final concentration of 0,5 
µg/ml) of  EtBr. 
4. Pour the solution into the gel tray and insert the well comb.  
5. Let the gel harden. 
6. Remove well comb and place the gel into the electrophoresis chamber.  
7. Add 1 x TAE buffer until the gel is covered. 
8. Add loading buffer to your samples and apply on the gel.  
2.6 Protein	  techniques	  
Proteins are rapidly degraded, it is therefore important to work on ice, centrifuge at 4°C 
and include protease inhibitors in lysis buffer.  
 Protein	  extraction	  2.6.1
This method describes how to generate radioimmunoprecipitation assay (RIPA) buffer 
protein lysate. RIPA (RIPA buffer, BioRad) is a lysis buffer, which can be used to extract 
proteins from cultured mammalian cells, including pelleted suspension cells. 
Procedure:	  
1. Add 20 µl lysis buffer containing 1x protease inhibitor cocktail (PIC) (Roche) in 
25 x stock concentration, to 1 million cells. Adjust the volume dependent on the 
cell number you lyse.  
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2. Vortex tubes to loosen the clumps and put them on the rotator machine at 4°C for 
30 min to 1 hour. 
3. Centrifuge at 12000 x g or maximum speed for 15 minutes at 4°C. 
4. Transfer supernatant to a new chilled eppendorf tube on ice and mark the tubes. 
Store the lysate at -20°C. For long time storage it is recommended to store lysate at 
-70°C. 
 Protein	  concentration	  assessment	  	  2.6.2
The Bradford method is a spectrophotometric method for determining concentration of 
protein in solution. The procedure is based on the proportional binding of Coomassie blue 
to proteins. The higher concentration of protein, the more Coomassie will bind and the 
darker the protein solution becomes. The Bradford method was done prior to SDS-PAGE, 
described in the next subsection, for estimation of protein concentration in the lysate, to be 
able to apply equal amounts of proteins to each well.  
Procedure:	  
1. Prepare Bradford tubes according to your number of samples (two tubes per 
sample). Also prepare 10 tubes for generating a standard curve. 
2. Add 1 ml of Coomassie Blue dyes to each tube. 
3. For standards, add BSA (2 mg/ml) according to the table (two tubes of each):  
Standard	  1	   Standard	  2	   Standard	  3	   Standard	  4	   Standard	  5	  
0,5	  ml	   1,0	  μl	   2,0	  ml	   4,0	  ml	   8,0	  ml	  
 
4. Add 2 µl of your sample to the dye and mix. Check the color of the dye, it should 
be within the range of the standard, otherwise the concentration is too high or low 
and you need to adjust the amount added. 
5. Vortex the tubes gently. 
6. Incubate for 10-15 min and transfer samples to cuvettes before measuring 
absorbance at 595 nm on Ultraspec 2100 Pro UV/Vis Spectrophotometer 
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(Amershan Bioscience). Use 1 ml dye + 2 µl RIPA buffer as a reference for your 
samples lysed in RIPA buffer, and 1 ml dye as reference for the standard curve 
samples.  
7. Make a standard curve of the standard samples, with protein concentration on the x-
axis and absorbance at the y-axis. Calculate amount of protein from this standard 
curve. 
 	  SDS-­‐PAGE	  2.6.3
Sodium dodecylsulphate polyacrylamide gel electrophoresis (SDS-PAGE) is a method 
used routinely prior to Western blotting. Proteins are separated according to mass, after 
treatment with SDS. SDS is an anionic detergent that denatures the proteins and creates 
complexes between the protein and SDS. Due to the negative charge of SDS, the original 
charge of the proteins is irrelevant, and the proteins are given an overall negative charge.  
As the molecular mass is the determining factor in the electrophoresis, small proteins will 
move faster in the gel than larger proteins. High percentage of acrylamide will make 
proteins migrate slower in a gel than low percentage of acrylamide. By the use of a 
molecular standard with known molecular weight in kilo Dalton (kDa), the sizes of the 
separated proteins can be estimated. Protein separation was performed using CriterionTM 
TGXTM 10% (Bio-Rad) precast gels and 10 % mini protean TGX Precast gels (Bio-Rad). 
Preparing	  samples	  for	  SDS-­‐PAGE:	  
1. Dilute all samples to the same volume in RIPA-buffer, 
2. Add 6 x SDS loading buffer to each sample, recipe in appendix 3. 
3. Heat for 5 minutes at 96°C. 
Procedure:	  
1. Carefully pull out the comb of the premade gel. Wash the wells with dH2O to 
remove any excess gel or air bubbles.  
2. Place the gel into the Electrode Assembly.  
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3. Fill the inner chamber with 1 x running buffer, recipe in appendix 3, so that the 
wells in the gel are completely covered with buffer. Fill also the lower chamber 
with running buffer to cover the bottom of the gel.  
4. Carefully apply the samples by letting it sink down in the well. The Sample 
Loading Guide makes it easier to apply. Avoid overflow of the samples to 
neighboring wells. 
5. Apply the molecular standard; 6 µl Precision Plus ProteinTM dual color standard 
(Bio-Rad).  
6. Run the gel at 150 volts (V) for 15 min, followed by 200 V for approximately 45 
min.  
7. Dissemble the gel electrophoresis equipment. 
8. Wash the gel in dH2O 
Following SDS-PAGE, the gel can be further processed for Western blotting. Western blot 
is described in the next section, and recipes for the different buffers used in both SDS-
PAGE analysis and in Western blotting are listed in appendix 2. 
 Western	  blotting	  2.6.4
Western blotting is a technique used for detection of proteins by the use of antibodies after 
protein transfer from gel to membrane. After separation of proteins with SDS-PAGE, the 
proteins in the gel are transferred to a membrane in an electrical field. In this study, 
polyvinylidine fluorine (PVDF) (Immune-blot® PVDF, BioRad) membrane was used. 
Once the proteins are bound, blocking is done to prevent unspecific binding to the 
membrane. Proteins in the blocking solution will bind to all regions of the membrane, 
except for parts already occupied by proteins transferred from the gel. This will prevent the 
antibodies from binding non-specifically to the membrane. The next step is to incubate the 
membrane with the desired primary antibody, specific for a protein. The secondary 
antibody, which will bind the primary antibody, is linked to the enzyme Horseradish 
Peroxidase (HRP). This enzyme will produce light upon developing, when a suitable 
substrate is added, in proportion with the amount of protein on the membrane. 
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Procedure:	  
Protein	  transfer:	  
1. Put the gel, outlined in the previous section, in transfer buffer (recipe in appendix 
3) for 1-2 min. 
2. Cut the PVDF membrane to appropriate size and activate it in methanol (Sigma 
Aldrich) for 15 sec. 
3. Wash the membrane in dH2O and put it in transfer buffer.  
4. Soak two 3 mm filters (BioRad) in transfer buffer. Thereafter, place one of the 
filters in the blotting apparatus (Amersham ECL Semi-Dry Blotters TE 77 PWR, 
Amersham Bioscience). 
5. Place the membrane on the top of the filter. 
6. Place the gel on the membrane and the last filter on top of the gel. Press out air 
bubbles. Place the lid on the apparatus. 
7. Run the blot at 1mAmp/cm3, equivalent to 130 mA for CriterionTM TGXTM  gels, at 
50 V for one hour. 
Detection	  with	  antibody:	  
8. Block the membrane with 3% skimmed milk in tris-buffered saline with tween 20 
(TBS/T) (see recipe in appendix 3) at room temperature (RT) for 1 hour. 
9. Add the primary antibody in 3% skimmed milk/TBS/T, the dilution of antibody is 
different for different antibodies, dilute as recommended for your antibody. 
10. Incubate for 1 hour at RT or at 4°C overnight. 
11. Wash the membrane 3 x 20 min in TBS/T. 
12. Add the secondary antibody in 3% skimmed milk in TBS-T, dilute as 
recommended. Incubate for 1 hour at RT.  
13. Wash the membrane 3 x 20 min in 3% skimmed milk/TBS/T. 
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Developing	  blots:	  
14. Place the membrane in a plastic beaker and add the Super-Signal solution in 1:1 
ratio (SuperSignal® West Pica Chemiluminescent substrate, Thermo Scientific). 
15. Incubate for 5 min 
16. Place the membrane in the developer cassette. Close the cassette and proceed in the 
developer room. 
17. Turn off the light (only red light should be on). Remove the film (ECL hyperfilm, 
GE healthcare) from the box. Make a cut in the upper right corner of the film. Open 
the cassette and place the film on top of the membrane (a plastic film should be 
between the film and the membrane). Close the lid and expose the film before 
developing it (Curix 60, AGFA HealthCare). 
Stripping	  of	  membranes:	  
If more than one protein is to be investigated on the same blot, it needs to be stripped prior 
to reprobing with another antibody. RestoreTM PLUS Western Blot Stripping Buffer 
(Thermo Scientific) was used in this project for stripping. 
Procedure:	  
1. Reactivate the membrane in methanol for 15 sec. 
2. Wash the membrane x 1 in dH2O 
3. Wash the membrane x 1 in TBS/T 
4. If the signals are strong, cover the membrane in 10 x SDS running buffer, and heat 
it in the microwave until the point of boiling. If no strong signals are present, 
continue at point 7. 
5. Discard the buffer. 
6. Wash x 2 with TBS/T for 15 min, leave on tilting table at RT. 
7. Add the stripping buffer, leave on a tilting table for 15 min at RT. 
8. Block the membrane with 3% skimmed milk for 1 hour on tilting table at RT.  
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After stripping, the membrane is ready for incubation with a new primary antibody. 
 Cell	  preparation	  for	  flow	  cytometry	  2.6.5
In this project, flow cytometry was used to analyze the purity of the CD4+ T cells isolated 
from PBMC (section 2.1.2). Flow cytometry uses light scatter to measure intrinsic size and 
granularity of the cell. Prior to the flow cytometry analysis, the cells were labeled with a 
fluorochrome–conjugated antibody, fluorescein isothiocyanate (FITC) or allophycocyanin 
(APC) conjugated antibodies were used. The procedure for preparation of cells for flow 
cytometry analysis is described below. 500 000 cells were taken out for immunostaining 
prior to flow cytometry.  
Procedure:	  
1. Transfer cells to a 96-well tip-bounded plate (Nunc). Pipet 250 000 cells into each 
well. 
2. Spin down at 340 x g for 2 minutes at 4oC. Discard SN. 
3. Wash x1 by adding 150 µl PBS w/1% FCS and 0,05% Sodium Azid. 
4. Spin down as in step 2. 
5. Add antibody solution. Dilute the desired antibody according to the manufacturer’s 
instructions in PBS w/1% FCS and 0,05% NaAzid. 100 µl Ab-solution is used per 
1 x 106 cells. Adjust the volume accordingly.  
6. Leave on ice for 20 minutes. Cover with aluminum foil. 
7. Spin down as in step 2 and discard SN.  
8. Wash x 2 by adding 150 µl PBS w/1% FCS and 0,05% NaAzid, spin down as in 
step 2 in between. Discard SN. 
9. Resuspend in 100 µl PBS with PFA for fixation of the cells. Incubate for 10 min at 
RT.  
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10. Transfer suspension to a flow tube with 200 µl PBS w/1% FCS and 0,05% NaAzid. 
Cover tube with aluminum foil, and leave at 4 °C. The cells can now be stored up to 
7 days before the flow analysis begins.  
Flow	  cytometry	  for	  purity	  assessment	  of	  isolated	  CD4+	  T	  cells	  
250 000 prepared cells, see section above, were analyzed by flow cytometry (Facs Calibur, 
BD Biosciences) and data was processed and analyzed by the computer software 
CellQuestPro (BD Biosciences). 
2.7 	  Statistical	  analyses	  
The data produced by gene expression analysis and protein expression was analyzed by 
statistical methods. Statistical analysis utilized in this project is Student`s paired and un-
paired T-Test. Standard deviation (SD), standard error of the mean (SEM) were calculated 
by GraphPad Prism 6, in addition to the statistical analysis.  	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3 Results	  
The main objectives of this thesis are: (1) to investigate whether vitamin D alone is 
sufficient for regulation of target genes in CD4+T cells at the mRNA and the protein level, 
(2) correlate genotype of MS associated loci in TAGAP and IL2RA to their expression upon 
vitamin D treatment and (3) investigate if expression of target genes differ in healthy 
controls and MS patients. 
3.1 VDR	  expression	  in	  CD4+	  T	  cells	  
In the initial screening performed by Tone Berge, freshly isolated CD4+ T cells were 
stimulated to investigate vitamin D responsiveness of selected MS associated genes. In the 
current project, we wanted to use CD4+ T cells stored on liquid nitrogen. These cells have 
been isolated from MS patients and controls, and we have DNA available for genotyping. 
Each vial contains 2 million frozen cells, and to achieve sufficient numbers for our study, 
these cells have to be expanded prior to vitamin D treatment. To investigate vitamin D 
response in cells after expansion in the presence of αCD3/CD28 beads, cells were allowed 
to rest for 24 hours before addition of vitamin D or vehicle control in the presence or 
absence of αCD3/CD28 beads. In order for cells to be vitamin D responsive, the presence 
of the VDR is required and therefore we first wanted to evaluate whether cells treated in 
this manner did express VDR at the time of vitamin D addition i.e. after 24 hours resting. 
Freshly isolated CD4+ T cells from three healthy donors were activated with αCD3/CD28 
coated beads for 40 hours prior to bead removal and resting of the cells for 24 hours. Cells 
were harvested before stimulation (time 0), after 40 hours of stimulation (time 40) and 
after an additional 24 hours of resting (time 40+24). Protein expression of VDR was 
analyzed by western blotting, presented in figure 3.1, showing one out of the three repeated 
experiments. 
 
Figure 3.1: Western blot showing expression of VDR in CD4+ T cells. Freshly isolated CD4+ T 
cells were cultivated with αCD3/CD28 for 40 hours prior to removal of beads and a subsequent 
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resting of the cells for 24 hours. Cells were harvested at the time of activation (time 0); after 40 
hours (time 40) and after an additional 24 hours of rest (time 40+24). Lysates from 1 x 106 cells 
were applied per well. Lysate from 293T cells, overexpressing VDR (Santa Cruz) was used as 
positive control. The blot was reprobed with anti-ZAP70 that functions as loading control. The 
figure shows one out of three experiments. 
 
From the western blot (figure 3.1), we can see that VDR expression persisted 24 hours 
after removal of the beads. In conclusion, this means that the same stimulation conditions 
can be used for biobank samples.  
3.2 Vitamin	  D	  responsiveness	  of	  MS	  biobank	  samples	  
Tone Berge has shown that 10 nM (as compared to 1 and 100 nM) of the active form of 
vitamin D, 1,25(OH)2D3, induces maximum vitamin D response in CD4+ T cells as 
evaluated by measuring expression of CYP24A1 (Berge, unpublished data), a well-known 
VDR target gene [42]. Stimulation by addition 10 nm of 1,25(OH)2D3 will be referred to as 
“addition of vitamin D” throughout the results section. Vitamin D is solubilized in ethanol, 
which is used as vehicle control throughout the study.   
 Vitamin	  D	  responsiveness	  in	  CD4+	  T	  cells	  3.2.1
Upon drawing fresh blood from MS patients, peripheral blood mononuclear cells (PBMC) 
were isolated and CD4+ T cells were purified from PBMCs by negative selection 
(AutoMACS Pro Separator, Miltenyi Biotech, performed by members of the MS research 
group). Live cells were stored in liquid nitrogen as part of the ‘Oslo MS Biobank’. To 
establish a protocol for optimal cultivation- and thawing- conditions of cells, we performed 
a pilot study. The aim of this pilot study was to verify that the stressful environment 
inflicted on the cells when performing cryopreservation did not affect the vitamin D 
responsiveness of selected MS associated genes, as well as to establish a protocol to 
analyze vitamin D responsiveness of MS susceptibility genes in CD4+ T cells that were 
previously stored in our local biobank. CD4+ T cells from healthy controls (n = 2) were 
therefore thawed and expanded with αCD3/CD28 for 8 days. Removal of beads after 8 
days allowed cells to rest for 24 hours before addition of αCD3/CD28 beads together with 
vitamin D or vehicle control. Expression of VDR and CYP24A1, both established VDR 
target genes [42] were measured relative to the reference genes TBP and 18S rRNA, which 
gave comparable results. Expression relative to the TBP is presented in Figure 3.2. 
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Figure 3.2: CD4+ T cells from the MS biobank are responsive to vitamin D. CD4+ T cells from 
healthy controls (n = 2) were cultured with αCD3/CD28 beads for 8 days, before removal of beads 
for 24 hours to rest the cells prior to activation with αCD3/CD28 and addition of vitamin D or 
vehicle control. Cells were harvested after resting (time 0) and after 24 hours with αCD3/CD28 
and vitamin D or vehicle control as indicated in the figure. Expression of VDR and CYP24A1 was 
measured by qPCR. Bars display mean expression of VDR (A) and CYP24A1 (B) relative to TBP 
with standard error of the mean (SEM).  
 
The relative expression of VDR in rested cells shows low expression, however the 
expression was induced in αCD3/CD28 activated CD4+ T cells after 24 hours, and even 
further induced in activated CD4+ T cells cultivated with vitamin D. CYP24A1 was 
induced in activated cells with vitamin D. These results indicated that cryopreserved CD4+ 
T cells are vitamin D responsive upon thawing.  
 Is	  vitamin	  D	  alone	  sufficient	  to	  regulate	  gene	  expression	  of	  its	  target	  3.2.2
genes	  in	  CD4+	  T	  cells?	  	  
Two vials of CD4+ T cells from the MS biobank were thawed for cultivation and expanded 
with αCD3/CD28 and IL-2 as described in the method chapter, section 2.3.1, in two 
separate cultivations. After 8 days in culture, αCD3/CD28 beads were removed. The cells 
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were rested for 24 hours (time point 0) prior to treatment with vitamin D or vehicle control 
with or without αCD3/CD28 beads. Cells were harvested after 24 and 48 hours of 
treatment and the relative expression of VDR, CYP24A1, TAGAP and IL2RA (figure 3.3 
and 3.4) was measured. We know from the previous section that VDR and CYP24A1 are 
vitamin D responsive genes using this stimulatory regime (in the presence of αCD3/CD28) 
and that TAGAP and IL2RA are vitamin D responsive in the presence of αCD3/CD28 
beads in freshly isolated cells (Berge, unpublished).  
 
Figure 3.3: Cryopreserved CD4+ T cells are responsive to vitamin D. CD4+ T cells from the 
MS biobank were co-cultured with αCD3/CD28 for 8 days before 24 hours rest by removal of 
beads. After 24 hours, αCD3/CD28 beads were added and cells stimulated with vitamin D or 
vehicle control in the absence or presence of αCD3/CD28, and harvested after 3, 24 and 48 hours. 
Expression of genes is presented relative to TBP. Bars display mean +/- SEM. A) Relative 
expression of VDR. B) Relative expression of CYP24A1.  	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As expected from the pilot experiment presented in figure 3.2, VDR expression is induced 
after 24 hours by αCD3/CD28 beads alone (figure 3.3 A), however, addition of vitamin D 
further enhances VDR expression. No further increase in VDR expression was observed 
after 48 hours in culture. Vitamin D alone did not give rise to increased VDR expression 
even after 48 hours. CYP24A1 expression was not induced upon activation of the cells with 
αCD3/CD28 beads, although, addition of vitamin D to the αCD3/CD28 treated cells 
resulted in a rise of CYP24A1 expression, which reached a maximum after 48 hours. 
Addition of vitamin D alone gave rise to expression of CYP24A1, although to a lower level 
than in combination with αCD3/CD28 beads. This indicates that vitamin D alone is 
sufficient to trigger a VDR response in CD4+ T cells in vitro.  
The relative expression of TAGAP (figure 3.4.A) seemed to be reduced in activated cells 
after 48 hours, and the expression was even further reduced with the addition of vitamin D. 
Vitamin D alone does not seem to have the same effect as in the presence of αCD3/CD28 
beads. The results in figure 3.4 B indicates an induction of IL2RA expression in 
αCD3/CD28 stimulated cells, which appears to be induced further with addition of vitamin 
D after 48 hours. Vitamin D alone is not sufficient to trigger a rise of IL2RA expression.  
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Figure 3.4. Cryopreserved cells are responsive to vitamin D. CD4+ T cells from the MS 
biobank were co-cultured with αCD3/CD28 for 8 days before 24 hours rest by removal of beads. 
After 24 hours, cells were activated and stimulated with vitamin D or vehicle control in the absence 
or presence of αCD3/CD28, and harvested after 3, 24 and 48 hours. Expression of genes is 
presented relative to TBP. Bars display mean +/- SEM. A) Relative expression of TAGAP. B) 
Relative expression of IL2RA.  
 
From these initial experiments we concluded that CD4+ T cells are vitamin D responsive 
after cryopreservation, however, a higher vitamin D dependent response is observed in the 
presence of αCD3/CD28 beads. 
3.3 Genotyping	  
To investigate whether the in vitro vitamin D responsiveness of the MS associated genes 
identified, i.e. TAGAP and IL2RA, is dependent on the genotype of their respective MS 
associated loci, the next step was to genotype the SNPs of interest in samples from MS 
patients and controls where live CD4+ T cells are stored in our local biobank. Samples 
were genotyped for each specific SNP by allele specific PCR, using TaqMan probes with 
	   55	  
one VIC-labeled probe and one FAM-labeled probe for the different alleles as described in 
section 2.5.2. 
 Genotyping	  of	  MS	  biobank	  samples	  3.3.1
For TAGAP, rs1738074 was genotyped as this SNP has been reported in the immunochip 
study to display the highest MS association signal in the TAGAP gene region [9]. For 
IL2RA, the rs7090512 was genotyped. This SNP is in the promoter region of IL2RA, and 
was identified as a secondary signal to the rs3118470 SNP identified in the GWAS study 
published in 2011 [14]. Figure 3.5 shows the genotyping results of rs173804 and 
rs7090512, presented in an allelic discrimination plot for each SNP. 
 
Figure 3.5: Genotyping of rs1738074 and rs7090512. Each dot represents one sample, either 
from an MS patient or a healthy control for rs1738074 (A) and rs7090512 (B). Allele 1 is 
represented in red where the VIC-labeled probe is attached, and represent the nucleotide G for both 
SNPs. Allele 2 is showed in blue where the FAM-labeled probe is attached, which represent the 
nucleotide A in both SNPs. The green dots represent heterozygous samples, where signals from 
both the VIC-labeled and the FAM-labeled probe are detected.  
	  
The 1000 genomes project [65] suggests a minor allele frequency of 0,47 for the nucleotide 
A in rs1738074 and 0,31 for the nucleotide G in rs7090512 in Utah residents with ancestry 
from northern and western Europe (CEU). Table 3.1 presents an overview over the 
genotype frequency expected calculated from the allele frequencies and the observed 
genotype frequency for the SNPs in this study. 
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Table 3.1: Expected and observed genotype frequency of rs1738074 (TAGAP) and rs7090512 
(IL2RA) 
SNP	   Combinations	   Theoretical	  genotype	  freq.	   Observed	  genotype	  freq.	  
	  	   AA	   25,0	  %	   19,0	  %	  
rs1738074	   AG	   50,0	  %	   57,0	  %	  
	  	   GG	   25,0	  %	   24,0	  %	  
	  	   AA	   52,0	  %	   47,6	  %	  
rs7090512	   AG	   40,0	  %	   42,9	  %	  
	  	   GG	   8,0	  %	   9,5	  %	  
 
3.4 Preparing	  qPCR	  set-­‐up	  	  
 Primer	  limited	  –	  optimizing	  qPCR	  conditions	  3.4.1
We decided to explore duplexing of qPCR for the genes of interest, TAGAP, IL2RA or 
CYP24A1 with the TBP reference gene. If successful, this would be both time- and reagent-
saving, and more accurate since cDNA are pipetted simultaneously into two assays thereby 
eliminating pipetting variation. Standard curves and amplification plots were closely 
studied for each assay run alone or in combination with TBP, and results indicated that 
both CYP24A1 and IL2RA allowed duplexing based on the optimal PCR efficiency 
calculated from the data. However, that was not the case for IL2RA (data not shown). 
When IL2RA was tested in duplexing with TBP, the amplification of TBP failed as the 
IL2RA assay used up all the reagents in the PCR-reaction. In order to solve this problem, 
an experiment with different dilutions of IL2RA probe was executed. Optimizing primer-
limited conditions is about testing different dilutions of the primer utilizing most of the 
reagents. The experiment was executed with eight different dilutions of the IL2RA probe, 
in eight different samples indicated by numbers in the figure below presenting the results 
from the primer-limited experiment. 
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Figure 3.6:  Amplification plot of the primer-limited experiment, with eight samples containing 
different amounts of the FAM-labeled IL2RA probe. The amplification plot is numbered according 
to primer dilution, representing amplification of the different samples. The plot in the lower right 
provides a detailed overview at the point of amplification to the threshold. 
 
By making a primer-limited experiment, the delta Rn is decreased, which means less usage 
of the common PCR reagents when amplifying the most highly expressed gene. However, 
a condition where the cycle number (CT) was unchanged was chosen. Using the optimal 
condition gave rise to optimal amplification of the TBP reference gene when run in duplex. 
 Quality	  control	  of	  reference	  genes	  3.4.2
Two reference genes were included in the qPCR analyses, TBP (run in duplex with the test 
genes) and 18S rRNA. The comparison of TBP and 18S rRNA (figure 3.7) shows a lower 
standard deviation for TBP than 18S rRNA. We concluded that TBP was the most stable 
reference gene in our samples.  All data was analyzed for both reference genes, but only 
one of the sets with relative to TBP will be presented here. 
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Figure 3.7: TBP and 18S rRNA quantified in qPCR using the standard curve method. The 
graph displays the quantity of TBP and 18S rRNA for all samples. Standard deviation (SD) was 
measured within each group. 	  
Despite extensive attempts to optimize the duplexing conditions, it was revealed that the 
quantification of TBP in duplex with IL2RA deviated from the quantification of TBP in 
duplex with TAGAP and CYP24A1. However, TBP in duplex with the other two genes 
were perfectly aligned throughout all samples, see appendix 4. In conclusion to this, the 
expression of IL2RA is presented as relative to the mean of the other two TBP 
measurements throughout the rest of the result section.  
3.5 qPCR	  of	  VDR	  target	  genes	  in	  vitamin	  D	  treated	  CD4+	  T	  cells	  
from	  the	  MS	  biobank	  
Samples from the MS biobank were selected according to the genotype of rs7090512 and 
rs1738074. Samples from 18 donors, both healthy controls (n = 10) and MS cases (n = 8), 
were thawed for cultivation for the remaining analysis in this study. Figure 3.8 displays an 
aligned scatter plot of all 18 cell cultures cultivated and expanded in X-vivo medium with 
IL-2 and αCD3/CD28 beads, to show the variation in growth rates. Each culture was 
monitored independently to maintain the optimal growing conditions.  
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Figure 3.8. Aligned scatter plot of CD4+ T cell growth-rate. CD4+ T cells from 18 donors were 
thawed and expanded for seven to eight days in culture with αCD3/CD28 beads, X-vivo medium 
and IL-2 before removal of beads, 
 
The aim was to investigate if vitamin D regulation of TAGAP and IL2RA expression in in 
CD4+ T cells correlate with the genotype of MS associated loci in TAGAP and IL2RA to 
their expression upon vitamin D treatment. Finally, expression of these target genes was 
compared in healthy controls and MS patients. Cells were treated with vitamin D alone or 
in combination with αCD3/CD28. Cells were allowed to rest for 24 hours by removal of 
beads, prior to addition of vitamin D or vehicle control alone or in combination with 
αCD3/CD28 beads. Cells were harvested at the time of bead removal (designated time 0) 
and after 6, 24 and 48 hours of stimulation.  
 CYP24A1	  as	  a	  positive	  control	  for	  vitamin	  D	  response	  3.5.1
As for the initiating experiments, relative expression of CYP24A1 was measured as a 
control for the ability of vitamin D to induce transcription in activated CD4+ T cells 
(figure 3.9) 
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Figure 3.9: Relative expression of CYP24A1 CD4+ T cells. CD4+ T cells were left unstimulated 
or stimulated and exposed to vitamin D or vehicle control, with and without αCD3/CD28 beads for 
indicated time points, relative to TBP. The graph represents mean +/- SEM. Paired Student`s test 
was performed, where P < 0,05 was considered significant. Symbol is defined as * = p ≤ 0,05 
 
CD4+ T cell stimulated with αCD3/CD28 beads in the presence of vitamin D gave rise to 
significantly higher expression levels as opposed to αCD3/CD28 beads in the absence of 
vitamin D after 48 hours. Although vitamin D alone did not give rise to significant increase 
in expression levels as opposed to vehicle control, the result indicates that vitamin D alone 
is enough to trigger CYP24A1 expression.  
 TAGAP	  is	  responsive	  to	  vitamin	  D	  	  3.5.2
When relative TAGAP expression was measured, the relative expression at time point 0 
was used to normalize against. The results presented indicate that vitamin D alone (figure 
3.10 A) is sufficient to regulate TAGAP expression through all time points. Expression of 
TAGAP is significantly reduced in cells treated with vitamin D. However, CD4 + T cells 
stimulated with αCD3/CD28 beads showed a transient increase of expression after six 
hours, before the expression of TAGAP was significantly reduced after 24 and 48 hours. 
Addition of vitamin D resulted in significant lower TAGAP expression after 24 and 48 
hours compared to vehicle control. We concluded that the expression level of TAGAP is 
reduced upon vitamin D treatment. 
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Figure 3.10: Relative expression of TAGAP is repressed upon vitamin D treatment. Human 
CD4+ T cells (n = 18) were cultivated for 8 days, and rested for 24 hours prior to addition of 
vitamin D or vehicle without (A) or without (B) addition of αCD3/CD28 as indicated in the figure 
legend. Graphs display mean relative expression of TAGAP divided by the relative expression in 
time point 0 +/- SEM. Paired Student`s T-test was performed, where P < 0,05 was considered 
significant. Symbols are defined as * = p ≤ 0,05, ** = p ≤ 0,001 and *** = p ≤ 0,0001  
	  
 IL2RA	  is	  responsive	  to	  vitamin	  D	  3.5.3
When measuring IL2RA in the same samples, we observed a significantly higher 
expression in vitamin D treated samples compared to corresponding control after 48 hours 
(Figure 3.11 A). Vitamin D treatment co-cultured with αCD3/CD28 beads gave rise to 
even higher level of IL2RA expression (approximately three-fold increase at 48 hours). 
When comparing vitamin D treatment of αCD3/CD28 stimulated cells with vehicle 
control, a significantly higher level of expression was observed after 24 and 48 hours. With 
this, we concluded that vitamin D alone is enough to trigger an induction of IL2RA 
expression after 48 hours, and vitamin D in the presence of αCD3/CD28 beads trigger the 
expression even further. 
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Figure 3.11: Relative expression of IL2RA is induced upon vitamin D treatment. Human CD4+ 
T cells (n = 18) were cultivated for 8 days, and rested for 24 hours prior to addition of vitamin D or 
vehicle without (A) or with (B) αCD3/CD28 beads as indicated in the figure legend. Both graphs 
display mean relative expression of IL2RA divided by the relative expression in time point 0 +/- 
SEM. Paired Student`s T-test was performed, where P < 0,05 was considered significant. Symbols 
are defined as * = p ≤ 0,05.  
 
3.6 Expression	  of	  IL2RA	  and	  TAGAP	  in	  individuals	  sorted	  on	  
genotype	  
As one of the main objectives in this study, the next step was to analyze whether the 
vitamin D responsiveness of MS associated genes was dependent on the genotype of their 
MS associated loci. 
 Does	   TAGAP	   expression	   after	   vitamin	   D	   addition	   associate	   with	  3.6.1
rs1738074	  genotypes?	  
The samples were sorted according to the genotype of the MS-associated rs1738074, to 
analyze whether there were any differences in TAGAP expression. The SNP analyzed is 
located in the 5` UTR region of TAGAP. The risk allele of rs1738074 is ‘G’. Vitamin D 
responsiveness of TAGAP in CD4+ T cells from donors homozygous for ‘G’ (n = 7) or 
homozygous for the non-risk allele, ‘A’ (n = 6), were compared. The results are presented 
in figure 3.12. 
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Figure 3.12: TAGAP expression in samples from individuals sorted on rs1738074 genotype. 
The graphs display the mean relative TAGAP expression relative to TBP+/- SEM,(n (AA) = 6, n 
(GG) = 7) in (A) vitamin D treated cells and in vehicle control and (B) in vitamin D treated cells in 
the presence of αCD3/CD28 beads and the corresponding vehicle control. Unpaired Student`s T 
test was performed, P = <0,05 was considered significant. No significant changes were detected 
 
For all time points, both in untreated and vitamin D treated samples (except 6 hours with 
αCD3/CD28), an increase in TAGAP expression was observed in individuals homozygous 
for the G-allele. This was however not significant. Although, in vitamin D treated cells 
with αCD3/CD28 beads as well as the corresponding control, a reduction of TAGAP 
expression was seen after 24 and 48 hours in both homozygous groups (figure 3.12 B).  
 Does	   IL2RA	   expression	   after	   vitamin	   D	   addition	   associate	   with	  3.6.2
rs7090512	  genotype?	  
The samples were sorted according to the genotype of the MS-associated rs7090512 in the 
IL2RA promoter region, where G is the risk allele. The gene expression data obtained from 
the qPCR experiments was used to compare the 13 individuals genotyped of which eight 
donors were of genotype ‘AA’ and five were of genotype ‘GG’.  
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Figure 3.13. IL2RA expression in samples from individuals sorted on rs7090512 genotype. The 
graphs display the mean IL2RA expression relative to TBP +/- SEM, (n(AA) =8, n(GG) = 6), in (A) 
vitamin D treated cells and vehicle control and (B) in vitamin D treated cells in the presence of 
αCD3/CD28 beads and the corresponding vehicle control. Unpaired Student`s T test was 
performed, P = <0,05 was considered significant. No significant changes were detected.  
 
Although no significant changes were detected in the analysis, also here some consistent 
trends were observed. Samples homozygous for G showed lower expression as opposed to A 
in all indicated groups. Increased IL2RA expression compared to corresponding controls is 
observed at time point 48 in samples treated with vitamin D alone or together with 
αCD3/CD28. However, no significant difference is observed between the two groups.  
3.7 Comparison	  of	  CYP24A1,	  TAGAP	  and	  IL2RA	  expression	  in	  MS	  
cases	  and	  healthy	  controls	  
As mentioned earlier, the cells used in this study are from both healthy controls (HC) (n = 
10) and MS patients (n = 8). We wanted to see if the expression pattern of the vitamin D 
responsive genes, i.e. CYP24A1, TAGAP and IL2RA differs between MS patients and 
healthy controls upon vitamin D treatment. The data presented in this section is therefore 
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divided into “MS” and “HC” groups. Although no significant changes were detected in the 
relative expression of CYP24A1 (figure 3.14), a non-significant trend can be observed 
where MS patients appear to express higher levels than healthy controls. 
 
 
Figure 3.14 Relative CYP24A1 expression in CD4+ T cells from MS patients and healthy 
controls. The graph displays the mean CYP24A1 expression relative to TBP +/- SEM, (n(HC) =10, 
n(MS) = 8) in samples treated as indicated in the figure. Unpaired Student`s T-test was performed 
on all time points, P < 0,05 was considered significant. No significant changes were detected 
 
 Relative	   expression	   of	   TAGAP	   differ	   between	   healthy	   controls	   and	  3.7.1
MS	  patients	  upon	  vitamin	  D	  treatment	  
When comparing TAGAP expression in MS cases and healthy controls, as seen in figure 
3.15, one can see that CD4+ T cells from healthy controls display higher expression in all 
groups compared with CD4+ T cells from MS patients. Significant groups are labelled with 
a star in the figure. Interestingly, upon vitamin D treatment alone there is a significantly 
reduction of TAGAP expression in MS patients compared to controls after 24 and 48 hours. 
CD4+ T cells stimulated with αCD3/CD28 beads in addition to vitamin D treatment also 
indicated lower expression levels of TAGAP as opposed to the respective vehicle, but this 
was only significant after 24 hours. In conclusion, the relative expression of TAGAP is 
lower in MS patients than in HC, in particular upon vitamin D treatment. 
	   66	  
 
Figure 3.15: Relative TAGAP expression is lower in MS than in HC. The graphs display the 
mean TAGAP expression relative to TBP +/- SEM, (n(HC) =10, n(MS) = 8) in samples treated as 
indicated in the figure. Unpaired Student`s T-test was performed on all time points, P < 0,05 was 
considered significant. Symbols are defined as: * = p ≤ 0,05 A) Expression of TAGAP relative to 
TBP in CD4+ T cells treated with vitamin D, and vehicle control. B) Expression of TAGAP relative 
to TBP in CD4+ T cells treated with vitamin D + αCD3/CD28 and the corresponding vehicle 
control. 
 
 Does	   the	   vitamin	   D	   responsiveness	   of	   IL2RA	   differ	   in	   CD4+	   T	   cells	  3.7.2
from	  healthy	  controls	  or	  MS	  cases?	  
The relative IL2RA expression in CD4+ T cells from MS cases and healthy controls was 
evaluated and the data is presented in figure 3.16. The figure is divided into MS and 
healthy controls groups. In all groups, IL2RA expression was lower in CD4+ T cells from 
MS patients compared to healthy controls, however, this was not significant. To conclude, 
the expression level of IL2RA does not differ significantly between MS cases and healthy 
controls. 
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Figure 3.16: Relative IL2RA expression in CD4+ T cells from MS cases and healthy controls. 
The graphs display the mean IL2RA expression relative to TBP +/- SEM, (n(HC) =10, n(MS) = 8) 
in samples treated as indicated in the figure. Unpaired Student`s T-test was performed on all time 
points, P < 0,05 was considered significant. No significant changes were detected. A) Expression of 
IL2RA relative to TBP in samples treated with vitamin D and the corresponding vehicle. B) 
Expression of IL2RA relative to TBP in samples treated with vitamin D in the presence of 
αCD3/CD28 beads and the corresponding vehicle. 
 
3.8 Protein	  expression	  analysis	  
 Does	  vitamin	  D	  affect	  protein	  expression	  of	  TAGAP	  and	  IL2RA?	  	  3.8.1
We have shown that gene expression of TAGAP and IL2RA is regulated by vitamin D in 
CD4+ T cells (figure 3.10 and 3.11 in this thesis and Berge, unpublished). To analyze 
whether this effect at the mRNA level is also detected at the protein level, CD4+ T cells 
from the MS biobank (n = 3) were thawed up and treated as described in section 2.3.1. 
Whole cell lysates were made from cells harvested prior to (time 0) and 24 and 48 hours 
after vitamin D and αCD3/CD28 addition. TAGAP and IL2RA expression was evaluated 
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by immunoblotting, figure 3.17 shows expression in one of the three donors. The 
remaining immunoblots are provided in appendix 4 
 
Figure 3.17: Western blot analysis of IL2RA and TAGAP in vitamin D treated CD4+ T cells. 
CD4+ T cells were treated as indicated and whole cell lysates were applied on an SDS 
polyacrylamide el prior to immunoblotting. A) The blot was probed with anti-IL2RA antibody. The 
blot was stripped and reprobed with anti-TAGAP antibody and anti-aectin antibody, which served 
as loading control. IL2RA was detected by using primary anti-IL2RA polyclonal antibody, TAGAP 
was detected by using primary anti-TAGAP polyclonal antibody and loading control (beta-actin) 
was detected by anti-actin polyclonal primary antibody. All secondary antibodies were HRP-
conjugated. 17 μg	  of	  total	  protein	  was	  applied	  in	  each	  well	  in	  this	  experiment.	  B)	  Quantification 
of the IL2RA protein level in CD4+ T cell lysates from three donors normalized to loading control 
signals. The graph display mean and bars represent the SEM. Multiple paired Student`s T test was 
performed to check for significant changes in vitamin D treated CD4+ T in the absence and 
presence of αCD3/CD28 beads compared to the corresponding control and to time 0. P < 0,05 was 
considered significant. No significant changes were detected.	  	  
When using the IL2RA antibody, several bands, i.e. at approximately 60, 55, 40, 35 and 20 
kDa were observed. Ensembl3 lists four different isoforms at 30, 29, 22 and 12 kDa, and 
these do not exactly match the size of the bands we observed. We chose to quantify the 
band slightly above 50kDa, as this is the size of the IL2RA isoform recognized by the 
IL2RA antibody according to the distributer of the antibody. An up-regulation of IL2RA 
protein expression after stimulation with αCD3/CD28 beads is observed, which is 
expected as IL2RA increases upon T cell activation [53].Vitamin D in addition to 
αCD3/CD28 beads also implies further increase of IL2RA expression in the donor 
presented in figure 3.17 A. However, this varies from donor to donor, as this trend was not 
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observed when the signal from all three donors were quantified by ImageJ [66] and 
normalized to loading control (figure 3.17 B). When vitamin D was added alone, this only 
gives rise to weak bands that are comparable to the corresponding vehicle. Regardless, the 
intensity of the signals detected at approximately 40 and 20 kDa increased additionally in 
lysates with vitamin D and αCD3/CD28 beads, which are further discussed in chapter 4. 
Only two faint bands between 75 and 100 kDa were observed when the blot was reprobed 
with TAGAP antibody. Ensembl4 lists three isoforms at 80, 61 and 29 kDa. However, the 
distributor of the antibody lists four different isoforms, with one at 57 kDa in addition to 
the three already mentioned. When inspecting the band at approximately 80 kDa, αCD3/28 
seems to induce its expression. Signals detected in the blot incubated with anti-TAGAP 
were not quantified since these were weak and in too close proximity to other bands, in 
addition to uncertainties regarding what bands should be considered.  
To conclude, expression at the mRNA level is not fully in correspondence with the 
expression at the protein level. For the IL2RA protein, increased expression in activated 
cells correlates to the expression pattern at the mRNA level, although vitamin D alone had 
little effect at the protein level. For the TAGAP protein, the opposite effect is observed at 
the protein level in contrast to the mRNA level.  	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4 Discussion	  
In this study we have explored the vitamin D responsiveness of two MS associated genes 
in CD4+ T cells, and analyzed whether the expression is regulated by the genotype of the 
MS associated loci. At the end, data were sorted on healthy control and MS patients to 
study whether expression differs in CD4+ T cells from diseased and non-diseased 
individuals, and finally expression at the protein level was investigated. Subsequently, the 
discussion chapter is divided in three main subchapters, before some methodological 
considerations are discussed.  
4.1 Successful	  system	  to	  monitor	  gene	  regulation	  in	  CD4+	  T	  cells	  
upon	  vitamin	  D	  treatment	  in	  vitro	  
The starting point for this project was the identification of several MS associated genes, 
containing VDREs in their regulatory region. Screening done in our lab revealed that two of 
these genes are regulated by vitamin D in vitro. Several groups have reported that naive T 
cells have low expression of VDR, which is induced upon T cell activation [11, 12, 41, 42] 
(Berge, manuscript in preparation). It has previously been shown that VDR is efficiently 
triggered only if 1,25(OH)2D3 is added to T lymphocytes with already high levels of VDR 
expression [42]. We could confirm that under the cultivation conditions used during this 
thesis, providing the two signals necessary for full T cell activation, that the cells are vitamin 
D responsive as evidenced by induction of CYP24A1 at the mRNA level. By Western 
blotting, we were able to show that VDR expression sustained 24 hours after αCD3/CD28 
removal, which is the time when vitamin D were added in these studies. In the VDR Western 
blot, ZAP-70 was used as a loading control. Since it did not give similar band intensities in 
all lanes, we cannot conclude whether the expression of VDR increased after αCD3/CD28 
stimulation, we know however, that it was expressed.  
 Vitamin	  D	  alone	  vs.	  vitamin	  D	  and	  αCD3/CD28	  beads	  4.1.1
Transcription of CYP24A1 was confirmed at the mRNA level in αCD3/CD28 activated 
CD4+ T cells treated with vitamin D, and in cells treated with vitamin D alone after 24 hours. 
The expression of CYP24A1 was further enhanced after 48 hours in the presence of vitamin D 
alone or in combination with αCD3/CD28, however, this increase of expression was only 
significant for cells that were treated with vitamin D in combination with αCD3/CD28. The 
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results imply that that vitamin D alone give rise to induction of CYP24A1 expression, which 
indicates that vitamin D alone is sufficient to trigger regulation of VDR target genes in CD4+ 
T cells. Whether this is the case for other vitamin D responsive genes in CD4+ T cells, in 
addition to TAGAP and IL2RA, remains to be studied. However, after 24 and 48 hours, a non-
significant trend for higher expression of CYP24A1 in MS cases was observed, which has 
also been reported in a Dutch cohort by Smolders and colleagues [67]. The observed result is 
consistent with MS patients being associated with low levels of vitamin D, as the function of 
CYP24A1 is to degrade the active form of vitamin D. Although, impact of other factors` 
involvement in decreased vitamin D response cannot be excluded, and in that case, one 
would expect reduced CYP24A1 expression as MS patients have lower levels of vitamin D. 
For instance, there are no recordings regarding serum level of vitamin D, outside activity 
level or dietary uptake of vitamin D of the patients included in this study.  
 Addition	  of	  vitamin	  D	  diminishes	  TAGAP	  expression	  in	  vitro	  4.1.2
In the main analysis, it was revealed that the expression of TAGAP, by the addition of 
vitamin D, was repressed. A decrease in TAGAP expression was significantly through all 
time points in cells treated with vitamin D alone, as well as in T cells activated with 
αCD3/CD28 and treated with vitamin D. Since TAGAP is reduced already after 6 hours, it 
could indicate that the TAGAP gene is a direct target of VDR.  
In addition, it has previously been reported by Mao et al. [61] that the expression levels of 
TAGAP in peripheral blood T cells rose transiently and reached maximum after 
approximately 4-6 hours stimulation with a combination of αCD3 and αCD28 monoclonal 
antibodies. This supports the findings in this study, where the same transiently increase 
was observed after 6 hours before a decrease in expression after 24 and 48 hours (figure 
3.10) in both activated CD4+ T cells in the addition to vitamin D, as well as in the 
corresponding control. The fact that the expression levels of TAGAP rise transiently upon 
T cell activation may also be indicative of its role in T cell activation.  
If the expected expression pattern of TAGAP in this study is similar to the findings done by 
Connelly et.al [62], where higher expression levels of TAGAP were observed in Chron`s 
patients than in healthy controls, a possible outcome could be higher levels of TAGAP 
expression in MS patients in comparison to samples from healthy controls. Surprisingly, a 
significant effect contradictory to this outcome was observed in vehicle control after 6 
hours. There was significantly decreased TAGAP expression in CD4+ T cells from MS 
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patients compared to healthy controls after 24 and 48 hours with vitamin D, and also in 
vitamin D in combination with the co-stimulatory activation signals after 24 hours. The 
expression of TAGAP is apparently lower in MS patients regardless of vitamin D or vehicle 
control. Treatment of CD4+ T cells with vitamin D in vitro lead to reduced expression of 
TAGAP in both healthy controls and MS patients, although not significant. 
Since the outcome differs from findings in other autoimmune diseases, new questions 
arise. Has TAGAP a different role in MS compared to i.e. Chron`s disease? Given the 
cohort more power, would samples from MS patients still be more responsive to vitamin 
D? 
 Addition	  of	  vitamin	  D	  induces	  IL2RA	  expression	  in	  vitro	  	  4.1.3
The study revealed that IL2RA is responsive to vitamin D alone. The expression of IL2RA 
at the mRNA level is induced in CD4+ T cells upon treatment with vitamin D alone or in 
combination with αCD3/CD28 beads. However, a significant increase of expression was 
only observed after 48 hours in vitamin D treated cells, and after 24 and 48 hours after 
vitamin D in addition to T cell activation. In contrast to TAGAP, the prolonged time to 
achieve a change in IL2RA regulation may imply that it is an indirect target gene of VDR. 
It could also be advantageous to measure the expression levels of IL2RA at a later time 
point in order to investigate at what time point it reaches maximum levels.  
As high levels of IL2RA expression is associated to autoimmune diseases [57, 58], one can 
hypothesize that MS patients show a decrease in expression of this gene in comparison to 
healthy controls. Although no significance changes were found, the observed trend in the 
vehicle controls supports this suggestion. Higher expression of IL2RA in vitamin D treated 
cells, with and without αCD3/CD28, was observed after 48 hours in both groups compared 
to the corresponding controls. 
Furthermore, it should be kept in mind that the patient cohort in this study has a mild 
course of disease, and all are untreated. Disease severity and treatment can alter the gene 
expression, in which case would not be discovered in this study, for neither of the studied 
genes.  
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 Does	  the	  mRNA	  expression	  level	  correlate	  with	  the	  protein	  level?	  4.1.4
The results from the protein expression analysis (section 3.8) showed increased IL2RA 
protein expression in activated cells together with vitamin D. This is consistent with the 
expression shown at the mRNA level. However, the same was not observed for cell lysates 
from cells treated with vitamin D alone. Interestingly, two other bands at approximately 40 
and 20 kDa showed the same expression pattern, also seen in the two other donors 
(Appendix 4C). Still, whether this is of scientific relevance, is to be determined. As 
described in the result section, there are four different isoforms of the IL2RA protein, and  
the sizes of the bands detected in the immunoblotting don’t comply with the suggested 
isoforms. Shift in migration pattern could be caused by different posttranslational 
modifications (PTMs) i.e. acetylation, methylation, phosphorylation or glycosylation. 
Two faint bands were observed for the TAGAP protein at approximately 80 and 90 kDa, 
for the blot showed in the result section. Multiple bands were also observed in the other 
two experiments, although these were not at the same sizes. At the mRNA level, the 
expression of TAGAP is transiently induced after 6 hours in the presence of αCD3/CD28 
beads. It cannot be excluded that this response is more slow at the protein level, hence the 
stronger bands after 24 and 48 hours.  
Due to time constraint, optimizing the conditions for the two antibodies was not 
performed. Among others, positive controls should be included to estimate the size of the 
expected protein bands. 
4.2 How	  is	  the	  expression	  of	  TAGAP	  and	  IL2RA	  regulated	  by	  the	  
presence	  of	  vitamin	  D?	  
Neither of the MS associated SNPs studied in this project are located within the VDRE, but 
they are located within the regulatory regions of the genes. Next, I will discuss the possible 
roles of location of the respective VDREs and SNPs in gene regulation.  
 How	  does	  vitamin	  D	  diminish	  TAGAP	  expression?	  4.2.1
As previously described in the introduction, there are two VDREs, -10 kb to +5kb of the 
TAGAP gene. These are located in the non-coding regulatory region and in the first intron 
of the coding gene, and the MS associated rs1730874 SNP is located in the 5’ untranslated 
region (UTR), illustrated in figure 4.1.  
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Figure 4.1: Schematic illustration of VDRE and SNP localization relative to the TAGAP gene. 
There are two VDREs in the TAGAP gene. One of the VDREs is located at chr6: 159,471,316-
159.471,330, which is about 5000 bases upstream from the transcription site, and the other one is 
located in intron 1, chr6: 159,465,841-159,465,855. Our SNP of interest, rs1738074, is located at 
chr6: 159,465,977, which is in the promoter region of the gene. The chromatin assembly used is 
Human February 2009 (GRh37/hg19). 
 
The SNP is associated with a number of different binding sites for transcription factors 
revealed from ChIP-seq directed by ENCODE factorbook [51]. Handel et al. have also 
recently located rs1738074 within the DNA that is immunoprecipitated from CD4+ T cells 
in VDR chromatin immunoprecipitation combined with DNA sequencing (ChIP-seq) 
experiments [68]. These findings show that VDR bind DNA in a region where this MS 
associated SNP is located, indicating that this SNP may impact the binding of VDR, or 
binding of possible co-factors. Due to the location, one could speculate whether this SNP 
can alter the binding affinity of transcription factors in this genetic region, resulting in 
diminished expression of the gene. Of the two VDREs in the TAGAP gene, the one located 
in the non-coding regulatory region is not associated with DHS or binding sites for 
transcription factors. However, the intronic VDRE is located on DHS clusters [51], and in 
close proximity to rs1738074 and is also within suggested binding region for some general 
transcription factors.  
 How	  does	  vitamin	  D	  enhance	  IL2RA	  expression?	  4.2.2
There is one VDRE, -10kb to +5 kb of the IL2RA gene. This is located in the non-coding 
region upstream from the transcriptional start site. The SNP rs7090512 is also located in 
this region, as illustrated in the figure 4.2. 
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Figure 4.2: Schematic illustration of VDRE and SNP localization relative to the IL2RA gene. 
There is one VDRE in the regulatory region of the IL2RA gene, located at chr10: 6,113,820 – 
6,113,839. The SNP of interest, rs7090512, is located at chr10: 6,110,829, upstream from the 
transcription site. The chromatin assembly used is Human February 2009 (GRh37/hg19). 
 
The rs7090512 SNP is not located within the VDRE, or within the actual coding region. It 
is located between two DHS cluster sites, indicated by the ENCODE project [51]. There 
are no transcription factors known to bind in the area around rs7090512 or the region 
around the VDRE. However, the VDRE is associated with DHS clusters indicating a 
potential role in gene regulation. Although there are no suggested transcription factors 
binding sites located within the region of the VDR or rs7090512, there are also several 
proposals where VDR bound to VDRE can interact with transcription factors by DNA 
looping, or by the recruitment of co-regulators [35, 46, 69]. 
4.3 Vitamin	  D	  responsiveness	  may	  correlate	  to	  genotype	  of	  MS	  
associated	  loci	  
No significant changes in expression of IL2RA and TAGAP were observed when sorting on 
genotype of rs7090512 and rs1738074, respectively. In addition to compare expression in 
samples from homozygous individuals for each SNP, we gave the cohort more power by 
increasing the size of the groups. This was done by including samples from heterozygous 
individuals in the analyses and thus group samples from individuals homozygous for the 
risk or non-risk allele, with samples from individuals that are carriers of risk or non-risk 
allele (data not shown). However, that did not result in any significant changes for the 
expression of TAGAP, even when correcting for the disease-induced differences, by 
excluding these from the analysis. One cannot exclude that this SNP is an imperfect proxy 
marker for a true MS risk SNP, meaning that there is a possibility for SNP-driven gene 
regulation to exist outside the local linkage disequilibrium (LD) structure, but this would 
not be detected it in this study. Although, for the IL2RA associated SNP, there was a 
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significant higher expression of IL2RA in in all carriers of the risk allele compared to 
homozygous individuals for the non-risk allele after 48 hours in activated and vitamin D 
treated cells after 24 hours (Appendix 4C). This suggests that rs7090512 is functional, or is 
in high LD with a functional SNP.  
4.4 Methodological	  considerations	  
 Vitamin	  D	  treatment	  –	  locally	  high	  concentrations	  	  4.4.1
In initial dose-response analyses, 1, 10 or 100 nM of vitamin D was added to CD4+ T cells 
in addition to αCD3/CD28. CYP24A1 reached maximum expression levels with 10 nM. 
Therefore, 10 nM of vitamin D has been utilized in the experiments performed in this 
project. Normal serum levels of the vitamin D precursor, 25(OH)D3, is about 25-170 nM, 
and serum levels of the active 1,25(OH)2D3 is a 1000 fold lower, 60-110 pM. The 
conditions in which these experiments were executed in were therefore all in apparently 
high concentrations. However, the enzyme CYP27B1 is widely expressed [12, 42, 70, 71], 
and has earlier this year also been identified in activated T cells by Kongsbak with 
colleagues [72], meaning that T cells possess the ability to convert the vitamin D precursor, 
25(OH)D3, to active vitamin D, thereby being able to make locally high concentrations of 
vitamin D in vivo. Further, it has also been shown that DBP in serum sequesters 25(OH)D3 
and thereby inhibits the production of 1,25(OH)2D3 from 25(OH)D3 in T cells in vivo [72]. 
However, the medium utilized in this project is serum free. 
 RNA	  and	  qPCR	  4.4.2
RNA concentration, as well as the 260/230 and 280/230 ratios were measured for every 
sample on Nanodrop, although, these values do not say anything about degradation of RNA. 
However, Bioanalyzer measures the RNA integrity, and gives a RIN value that says 
something about the RNA quality, and whether it has been degraded. In this project, only a 
selection of samples was processed on the Bioanalyzer to obtain their respective RIN value. 
There were no indications of possible RNA degradation, but the possibility for degraded 
samples should still be considered. 
Due to the big number of samples, cDNA synthesis was performed in two rounds and each 
qPCR assay was run in two separate 384-well plates, and considering comprehensive 
pipetting, this was performed on two subsequent days. Run-to-run variations were limited to 
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the best of our abilities by making a common mastermix for each assay. The remaining 
mastermix was stored at 4°C until the next day. 	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5 Summary	  of	  findings	  
In chapter 1 the aims of this study were outlined, and in chapter 3 the results were 
presented, and subsequently discussed in chapter 4. In this final chapter, I will summarize 
and conclude the findings of this project, as well as suggest studies for future work. 
5.1 Conclusion	  –	  part	  1	  
The first aim of this study was to investigate if vitamin D alone is sufficient to regulate 
expression of TAGAP and IL2RA at the mRNA- and the protein level in CD4+ T cells. We 
concluded that; 
• TAGAP and IL2RA are vitamin D responsive in CD4+ T cells.  
• In CD4+ T cells, vitamin D alone seems to be sufficient to trigger regulation of 
TAGAP, hence repression of TAGAP expression in vitro after 6, 24 and 48 hours. 
• Vitamin D alone is sufficient to trigger an induction of IL2RA expression in CD4+ 
T cells after 48 hours, although, by addition of activation beads, the expression is 
further induced in vitro. 
• No conclusions can be drawn regarding expression at the protein level, although 
there is a trend for higher expression of IL2RA protein in vitamin D treated cells 
co-cultured with αCD3/CD28. 
5.2 Conclusion	  –	  part	  2	  
Further, the study investigated if genotype of MS associated loci correlates with mRNA 
expression of IL2RA and TAGAP. 
• We concluded that there is no correlation between TAGAP expression and the 
presence of risk allele at rs1738074 in TAGAP in CD4+ T cells treated with 
vitamin D with or without αCD3/CD28 beads. 
• There is a correlation between the presence of risk allele at rs7090512 and 
increased expression levels of IL2RA in CD4+ T cells treated with vitamin and co-
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cultured with αCD3/CD28 beads after 24 hours, but there is no correlation in 
CD4+ T cells treated with vitamin D alone. 
5.3 Conclusion	  –	  part	  3	  
The third aim was to compare gene expression of vitamin D responsive genes in CD4+ T 
cells from healthy controls and MS patients.  
• We concluded that vitamin D treatment results in lower expression of TAGAP in 
CD4+ T cells from MS patients as opposed to healthy controls in vitro. 
• We concluded that vitamin D treatment does not result in expression differences of 
IL2RA in CD4+ T cells from healthy controls and MS patients in vitro. 
5.4 Future	  work	  
In this study, the expression of the VDR target genes IL2RA and TAGAP have been 
investigated upon vitamin D treatment by qPCR. For the short-term future perspective, I 
would optimize the immunoblotting conditions for both the IL2RA antibody and the 
TAGAP antibody. To confirm what bands to investigate for both proteins, additional 
optimization of the method should be performed. Furthermore, flow cytometry could be 
utilized to investigate the surface expression of IL2RA, as it will be transported to the cell 
surface to dimerize with the other two IL2 receptor chains. It would also be of great 
interest to study the expression of TAGAP and IL2RA in naive T cells. The MS research 
group is currently about to finish RNA sequencing of naive T cells isolated from patients 
and controls, enabling us to analyze such expression data for both IL2RA and TAGAP. In 
addition, monitoring of expression of both genes in T cells from patients before and after 
vitamin D supplement would also be of great interest to study the gene regulation. 
Further studies of TAGAP would also be of great interest to assess its particular role in MS, 
as very little is known about this gene in contrast to IL2RA. Excessive functional studies in 
T cells, i.e. by making TAGAP-plasmids for over expression, use siRNA for knock down 
or by the use of a mutated version can be performed and subsequently analyze T cell 
activation in vitro. In addition, it would be interesting to study how the TAGAP gene is 
regulated by VDR-RXR using ChiP assays, electro mobility shift assay (EMSA) or DNA 
foot printing, as it has been suggested that mechanisms involved in gene repression by 
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VDR may exclude binding to VDREs. Also, reporter gene assay could be performed to 
investigate the cellular mechanism of gene regulation.  	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Appendix	  1:	  List	  of	  abbreviations	  
Abbreviation	   Description	  
18S	  rRNA	   18S	  ribosomal	  RNA	  subunit	  
Ab	   Antibody	  
AP-­‐1	   Activator	  protein	  1	  
APC	   Antigen	  presenting	  cell	  
APC	   Allophycocyanin	  
bp	   Base	  pairs	  
CD	   Cluster	  of	  differentiation	  
cDNA	   Complementary	  DNA	  
ChIP	   Chromatin	  immunoprecipitation	  
CNS	   Central	  nervous	  system	  
CT	   Cycle	  threshold	  
CTLA-­‐4	   Cytotoxic	  T-­‐lymphocyte-­‐associated	  protein	  4	  
CYP	   Cytochrome	  P	  
Da	   Dalton	  
DBD	   DNA	  binding	  domain	  
DC	   Dendritic	  cell	  
dH2O	   Distilled	  water	  
DMSO	   Dimethyl	  sulfoxide	  
DNA	   Deoxyribonucleic	  acid	  
DR	   Direct	  repeat	  
EAE	   Experimental	  autoimmune	  encephalomyelitis	  
EDTA	   Ethylenediaminetettraacetic	  acid	  
EMSA	   Electro	  mobility	  shift	  assay	  
ER	   Everted	  repeat	  
et	  al.	   And	  others	  (Latin:	  et	  alii)	  
EtOH	   Ethanol	  
FCS	   Fetal	  Calf	  Serum	  
FITC	   Fluorescein	  isothiocyanate	  
FRET	   Fluorescent	  resonance	  energy	  transfer	  
g	   Gram	  
gDNA	   Genomic	  DNA	  
GDP	   Guanosine	  diphosphate	  
GEF	   Guanine	  nucleotide	  exchange	  factor	  
GTP	   Guanosine	  triphosphate	  
GWAS	   Genome	  wide	  association	  study	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Abbreviation	   Description	  
HC	   Healthy	  control	  
HCL	   Hydrogen	  chloride	  
HLA	   Human	  leukocyte	  antigen	  
HRP	   Horseradish	  peroxidase	  
i.e	   That	  is	  (latin:	  id	  est)	  
IFN-­‐γ	   Interferon	  gamma	  
Ig	   Immunoglobulin	  
IL-­‐2	   Interleukin	  2	  
IL-­‐2Rα	   Interleukin	  2	  receptor	  alpha	  
IMSGC	   International	  MS	  Genetics	  Consortium	  
ITAM	   Immunoreceptor	  tyrosine-­‐based	  activation	  motif	  
k	   Kilo	  
kb	   kilo	  bases	  
kDA	   kilo	  Dalton	  
l	   Liter	  
LAF	  bench	   Low	  air	  flow	  bench	  
LBD	   Ligand	  binding	  domain	  
LD	   Linkage	  Disequilibrium	  
LN	   Liquid	  nitrogen	  
m	   Milli	  
M	   Molar	  
MHC	   Major	  histocompability	  complex	  
ml	   Milliliter	  
mRNA	   Messenger	  RNA	  
MS	   Multiple	  sclerosis	  
n	   Nano	  
NaAzid	   Sodium	  Azid	  
NaCl	   Sodium	  chloride	  
NaOH	   Sodium	  hydroxide	  
NFAT	   Nuclear	  factor	  of	  activated	  T	  cells	  
NFκB	   Nuclear	  factor-­‐κB	  
ng	   Nano	  gram	  
nm	   Nanometer	  
NTC	   Non-­‐template	  control	  
PAGE	   Polyacrylamide	  gelelctrophoresis	  
PBMC	   Peripheral	  blood	  mononuclear	  cells	  
PBS	   Phosphate	  buffered	  saline	  
PCR	   Poly	  chain	  reaction	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Abbreviation	   Description	  
PTM	   Post	  translational	  modifications	  
PVDF	   Polyvinylidene	  fluoride	  
qPCR	   Quantitative	  PCR	  
rcf	   Relative	  centrifugation	  force	  
RIN	   RNA	  integrity	  number	  
RIPA	   Radioimmunoprecipitation	  assay	  
RNA	   Ribonucleic	  acid	  
RPMI	   Roswell	  Park	  Memorial	  Institute	  
RRMS	   Relapsing	  Remitting	  MS	  
RT	   Room	  temperature	  
RT	  -­‐	   Reverse	  transcriptase	  negative	  control	  
RXR	   Retinoid	  X	  receptor	  
SD	   Standard	  deviation	  
SDS	   Sodium	  dodecyl	  sulphate	  
SEM	   Standard	  deviation	  of	  mean	  
siRNA	   Short	  interfering	  RNA	  
SN	   Supernatant	  
SNP	   Single	  nucleotide	  polymorphism	  
TAE	  buffer	   Tris-­‐acetate	  EDTA	  buffer	  
TAGAP	   T	  cell	  activation	  Rho	  GTPase	  protein	  
TBP	   TATA-­‐box	  binding	  protein	  
TBS	   Tris	  buffered	  saline	  
TBS/T	   Tris	  Buffered	  Saline	  with	  Tween	  20	  
TCR	   T	  cell	  receptor	  
Th1	   T	  helper	  1	  
Th17	   T	  helper	  17	  
Th2	   T	  helper	  2	  
TNF-­‐α	   Tumor	  necrosis	  factor	  alpha	  
Treg	   T	  regulatory	  
UTR	   Untranslated	  region	  
UV	   Ultra	  violet	  
VDR	   Vitamin	  D	  receptor	  
VDR-­‐KO	   Vitamin	  D	  receptor	  knock	  out	  
VDRE	   Vitamin	  D	  responsive	  elements	  
ZAP-­‐70	   Zeta-­‐chain	  associated	  protein	  
μ	   Micro	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Amino	  acid	   Three	  letter	  code	   One	  letter	  code	  
Alanine	   Ala	   A	  
Arginine	   Arg	   R	  
Aspargine	   Asn	   N	  
Aspartic	  acid	   Asp	   D	  
Cystein	   Cys	   C	  
Glutamic	  acid	   Glu	   E	  
Glutamine	   Gln	   Q	  
Glycine	   Gly	   G	  
Histidine	   His	   H	  
Isoleucin	   Ile	   I	  
Leucine	   Leu	   L	  
Lysine	   Lys	   K	  
Methionine	   Met	   M	  
Phenylalanine	   Phe	   F	  
Proline	   Pro	   P	  
Serine	   Ser	   S	  
Threonine	   Thr	   T	  
Tryptophan	   Trp	   W	  
Tyrosine	   Tyr	   Y	  
Valine	   Val	   V	  
 
 
Nucleotide	   One	  letter	  code	  
Adenine	   A	  
Cytosine	   C	  
Guanine	   G	  
Thymine	   T	  
Purine	  (A/G)	   R	  
Pyrimidine	  (C/T)	   Y	  
Any	  nucleotide	   N	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Appendix	  2:	  Materials,	  equipment	  &	  
computer	  software	  
 
Material	   Catalog	  number	   Producer	  
Cell	  culture	   	  	   	  	  
1α,25	  dihydroxy	  vitamin	  D3	   D1530-­‐.1MG	   Sigma	  
Counting	  slides,	  dual	  chamber	  for	  cell	  
counter	  
145-­‐0015	   BioRad	  
Cryotubes™	  1	  ml	   375418	   Nunc™	  	  
Dimethyl	  Sulfoxide	   D8418-­‐100ml	   Sigma	  Aldrich	  
Dyna	  Mag™-­‐2	   123.21D	   Invitrogen	  
Dynabeads	  Human	  T	  activator	  CD3/CD28	   11131D	   Invitrogen	  
Dynabeads	  Untouched	  Human	  CD4	   11346D	   Invitrogen	  
Fetal	  Bovine	  serum	  EU	  approved	   1147-­‐9289	   Fischer	  scientific	  
Lymphoprep	   1115754	   Axis	  Shield	  
Recombinant	  Human	  IL-­‐2	   202-­‐IL	   R&D	  Systems	  
RPMI	  1640	   21875-­‐091	   GIBCO®	  Invitrogen	  
Tryphan	  Blue	  Solution	  (0,4	  %)	   T8154	   Sigma	  Aldrich	  
Hypodermic	  Needles,	  Microlance™	  3,	  	  18G,	  
40x1,25mmm	  
613-­‐3945	   BD	  MEDICAL	  
X-­‐vivo	  m/Gentamycin	  and	  phenolred	   04-­‐418F	   Lonza	  
Gene	  expression	  	   	  	   	  	  
DNase,	  RNase	  and	  protein	  free	  water	   2500010	   5	  PRIME	  
Eukaryotic	  18S	  rRNA	  Endogenous	  Control	  
(VIC/MGB	  probe,	  primer	  limited)	  
4319413E	   Life	  Technologies	  
Human	  TBP	  Endogenous	  Control	  (VIC/MGB	  
probe,	  primer	  limited)	  
4326322E	   Life	  Technologies	  
Maxima	  First	  Strand	  cDNA	  synthesis	  Kit	  for	  
RT-­‐qPCR	  
K1642	   Thermo	  Scientific	  
TagMan	  gene	  expression	  assay	  CYP24A1	  
Hs00167999_m1,	  750	  rxn	  
4351370	   Life	  Technologies	  
TagMan	  gene	  expression	  assay	  VDR	  
Hs00172113_m1,	  750	  rxn	  
4331182	   Life	  Technologies	  
Tagman	  Gene	  expression	  master	  mix	   4369512	   Life	  Technologies	  
TaqMan	  gene	  expression	  assay	  IL2RA	  
HS00907777_m1,	  750	  rxn	  
4351370	   Life	  Technologies	  
TaqMan	  gene	  expression	  assay	  TAGAP	  
HS00299284,	  750	  rxn	  
4351370	   Life	  Technologies	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Genotyping	   	  	   	  	  
DNase,	  RNase	  and	  protein	  free	  water	   2500010	   5	  PRIME	  
Genotyping	  assay,	  Assay	  ID:	  C_16095542-­‐10,	  
SNP	  ID:	  rs2104286	  (IL2RA)	  
4351379	   Life	  Technologies	  
Genotyping	  assay,	  Assay	  ID:	  C_1841420-­‐20,	  
SNP	  ID:	  rs7090512	  
4351379	   Life	  Technologies	  
Genotyping	  assay,	  Assay	  ID:	  C_2966098-­‐10,	  
SNP	  ID:	  rs1738074	  (TAGAP)	  
4351379	   Life	  Technologies	  
TaqMan	  Genotyping	  Mastermix	   4371355	   Life	  Technologies	  
SDS-­‐PAGE	  and	  Western	  blot	   	  	   	  	  
10	  %	  mini	  protean	  TGX	  Precast	  gels,	  10	  well	  
30	  ul	  
456-­‐1033	   BioRad	  
Actin	  (1-­‐19)	  antibody	   sc-­‐1616	   Santa	  Cruz	  
ECL	  developer,	  Super	  Signal	  west	  pico	   PIER34080	   Pierce	  
ECL	  Hyperfilm	  Amerham	   28-­‐9068-­‐37	   GE	  Healthcare	  
Gel	  loading	  tips	   613-­‐1046	   VWR	  
IL2RA	  antibody	  (N-­‐19)	   sc-­‐665	   Santa	  Cruz	  Biotech	  
Immun-­‐blot	  PVDF	  membrane	  for	  protein	  
blotting	  
162-­‐0177	   BioRad	  
Methanol	   32213-­‐5L	   Sigma	  
Peroxidase-­‐conjugated	  AffiniPure	  Goat	  Anti-­‐
Mouse	  IgG	  
115-­‐035-­‐146	   Jackson	  ImmunoResearch	  
Peroxidase-­‐conjugated	  AffiniPure	  Goat	  Anti-­‐
Rabbit	  IgG	  
111-­‐001-­‐003	   Jackson	  ImmunoResearch	  
Peroxidase-­‐conjugated	  AffiniPure	  Mouse	  
Anti-­‐Goat	  IgG	  
205-­‐035-­‐108	   Jackson	  ImmunoResearch	  
Precision	  Plus	  Protein™	  Standard	   161-­‐0374	   Bio	  Rad	  
Restore	  Plus	  Western	  blot	  stripping	  buffer	   PIER46430	   Thermo	  Scientific	  
Skim	  Milk	  powder	   70166-­‐5006	   Sigma	  Aldrich	  
TAGAP	  antibody	  (N-­‐16)	   sc-­‐324393	   Santa	  Cruz	  Biotech	  
ZAP-­‐70	  antibody	   sc-­‐32760	   Santa	  Cruz	  Biotech	  
Gel	  electrophoresis	   	  	   	  	  
1	  Kb	  Plus	  DNA	  ladder,	  200	  ug	   10787-­‐018	   Invitrogen	  
6x	  DNA	  Loading	  Dye	   	  R0611-­‐PR143	   Thermo	  Scientific	  
Ethidium	  Bromide	   190202	   MP	  Biomedicals	  
Saekem®	  LE	  Agarose	   50004	   Lonza	  
TAE	  Buffer	  (50	  x)	   R023	   G-­‐Bioscience	  
Bradford	  assay	   	  	   	  	  
Quick	  Start™	  Bradford	  1x	  Dye	  Reagent	   500-­‐0205	   BioRad	  
Quick	  Start™	  Bradford	  protein	  assay	  kit	  1	   500-­‐0201	   BioRad	  
RIPA	  buffer	   11542461	   Termo	  Scientific	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RNA	  isolation	  and	  quality	  assessment	  	   	  	   	  	  
Agilent	  RNA	  6000	  Nano	  Kit	  	   5067-­‐1511	   Agilent	  Technologies	  
Qiashredder	   79656	   Qiagen	  
RNase	  AWAY®	   7002	   VWR	  
Beta	  mercaptoethanol	   M6250	   Sigma	  Aldrich	  
RNeasy	  Plus	  mini	  kit	   74134	   Qiagen	  
Computer	  Software	   	  Version	   	  Company	  
Bioanalyzer	  Expert	  Software	   2100	   Agilent	  technologies,	  Inc.	  
Excel®	   14.2.5	  121010	   Microsoft	  
Graph	  Pad	  Prism	  6	   	  	   GraphPad	  Software,	  Inc.	  
Illustrator	  CC	  214	   18.01.00	   Adobe	  
NanoDrop	  2000	   	  1.6	   Thermo	  Scitentific	  
Viia™	  7	  Software	   1.0	   Applied	  Biosystems	  
Equipment	  
	  
Producer	  	  
2100	  Bioanalyzer	   	   Agilent	  
Centrifuge	  	   	   Eppendorf	  
ECL	  Semi-­‐Dry	  Blotter	  TE	  77	  PWR	   	   Amersham	  Biosciences	  
Electrophoresis	  Chamber	   	   Amersham	  bioscienses	  
FACS	  Calibur	  	   	   BD	  sciences	  	  
GeneGenius	  Gel	  Light	  Imaging	  System	   	   Syngene	  
Hypercasette™	   	   Amersham	  Biosciences	  
Nanodrop	  UV/Vis	  spectrophotometer	  2000	   	   Thermo	  Scientific	  
TC20™Automated	  Cell	  Counter	   	   Bio-­‐Rad	  
Ultra	  2100	  Pro	  UV/Vis	  Spectrophotometer	   	   Amersham	  Biosciences	  
Viia™	  7	  Applied	  Biosystems	   	   Life	  Technologies	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Appendix	  3:	  Recipes	  
Buffers	  for	  SDS-­‐PAGE	  and	  Western	  blot	  analysis:	  
10	  x	  Tris/Glycine/SDS	  running	  buffer	   	  
(25	  mM	  Tris,	  192	  mM	  0,1%	  SDS)	   2,5	  liters	  
Tris	  base	  (Mm	  =	  121,14	  g/ml)	   75	  g	  
Glycine	  (Mm	  =	  75,0666	  g/mol)	   360	  g	  
20%	  SDS	  (v/w)	   125	  ml	  
1	  x	  Tris/Glycine/SDS	  running	  buffer	   	  
(25	  mM	  Tris,	  192	  mM	  0,1%	  SDS)	   1	  litre	  
10	  x	  Tris/Glycine/SDS	  running	  buffer	   100	  ml	  
dH2O	   990	  ml	  
Transfer	  buffer	  for	  1	  hour	  semi-­‐dry	   	  
(25	  mM	  Tris,	  192	  mM	  glycine,	  10	  %	  methanol)	   2,5	  liters	  
Tris	  base	  (Mm	  =	  121,14	  g/ml)	   7,5	  g	  
Glycine	  (Mm	  =	  75,0666	  g/mol)	   36	  g	  
Methanol	   250	  ml	  
dH2O	   2,25	  liters	  
10	  x	  TBS,	  pH	  7.6	   	  
(100	  mM	  Tris,	  1,5	  M	  NaCl)	   3	  liters	  
Tris	  base	  (Mm	  =	  121,14	  g/ml)	   30,275	  g	  
NaCl	  (	  mM	  =	  58,44)	   216,4	  g	  
dH2O	   2,5	  liters	  
Add	  HCL	  	   to	  pH	  of	  7,6	  
1	  x	  TBS-­‐T	   	  
(10	  mM	  Tris,	  150	  mM	  NaCl,	  Tween	  20)	   3	  liters	  
10	  x	  TBS,	  pH	  7,6	   300	  ml	  
Tween	  20	   3	  ml	  
dH2O	   2,7	  liters	  
3%	  skimmed	  milk	  in	  1	  x	  TBS-­‐T:	   	  
(10	  mM	  Tris,	  150	  mM	  NaCl,	  Skimmed	  milk	  powder)	   300	  ml	  
Skimmed	  milk	  powder	   9,0	  g	  
1	  x	  TBS-­‐T	   up	  to	  300	  ml	  
6	  x	  Sample	  loading	  buffer:	   	  
(350	  nM	  Tris-­‐HCL	  pH	  6,8,	  10%	  SDS,	  30%	  Glycerol,	  0,175mM	  Bromophenolblue)	  
1,5	  M	  Tris-­‐HCL,	  pH	  6,8	   5,8	  ml	  
SDS	  (Mw	  =	  288,4	  g/mol)	   2,5	  g	  
Glycerol	   7,5	  ml	  
Bromophenolblue	  (Mm	  =	  691,9	  g/mol)	   3	  mg	  
β-­‐mercaptoethanol	   830	  μl	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Appendix	  4:	  Results	  
Quality	  control	  of	  reference	  genes	  
 
 
Supplementary figure 1: Quantified TBP from all duplex runs. TBP from all three runs aligned. TBP 
in duplex with IL2RA is not aligned with the other two. 
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Rs7090512	  –	  GG+GA	  versus	  AA	  after	  24	  hours	  
 
Supplementary figure 2: Expression of IL2RA in individuals sorted on rs7090512 genotype. All 
carriers of the risk allele give rise to higher expression levels than non-risk allele in vitamin D treated 
cells co-cultured with αCD3/CD28 after 24 hours.  
	  
Western	  blots	  of	  IL2RA	  and	  TAGAP	  protein	  
 
Supplementary figure 3: Western blotting analysis (n = 2) IL2RA was detected by using primary 
anti-IL2RA polyclonal antibody produced in rabbit, and secondary anti-rabbit-HRP antibody, TAGAP 
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was detected by using primary anti-TAGAP polyclonal antibody produced in goat and secondary anti-
goat-HRP antibody and loading control Actin was detected by anti-Actin polyclonal antibody 
produced in rabbit and secondary antibody anti-rabbit-HRP antibody.  A) 13,125 μg	  of	  total	  protein	  was	  used	  in	  the	  experiment,	  but	   in	  sample	  with	  vitamin	  D+αCD3/CD28	  24	  and	  48	  hours,	  only	  7,125	  μg	  and	  10,5	  μg	  was	  applied	  in	  due	  to	  lack	  of	  material.	  B)	  18,	  75	  μg	  was	  used,	  except	  for	  the	  well	  with	  vitamin	  D+αCD3/CD28	  beads	  24	  hours,	  where	  only	  2	  μg	  material	  was	  available.	  	  
